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ABSTRACT
Outbreaks of bacteria causing hospital- and community-acquired infections have dramatically 
increased in number over the recent years. For example, travelers become colonized by resistant 
bacteria and may transmit the strains to other people and to medical care settings when they 
return home. Th e challenge is new and problematic for laboratories performing bacterial 
diagnostics. Fast and highly specifi c tools are needed to identify and characterize resistant 
bacterial strains in order to prevent outbreaks in local hospitals. 
Th is thesis studies the fast identifi cation of virulence and resistance genes of the most important 
hospital-acquired (HA) bacteria. In addition, the applicability of rapid outbreak analysis for 
HA-bacteria using molecular methods outside of the national reference laboratory was studied. 
Th e aim of the study was to establish sensitive, reliable multiplex-PCR methods suitable for daily 
use in a microbiological diagnostic laboratory and to speed up the reporting of bacteria causing 
outbreaks. Another aim was to study the usefulness and functionality of a commercial repetitive 
PCR (DiversiLab) and compare it with reference molecular typing methods. Th e thesis also 
gives an overall view of the occurrence of HA-bacteria witnessed in the district of Helsinki and 
Uusimaa over the recent years.
Th e thesis consists of six studies on four diff erent bacterial species/types causing outbreaks: 
MRSA (methicillin-resistant Staphylococcus aureus), ESBL (Extended Spectrum Beta-
Lactamase)-producing Enterobacteriaceae, Acinetobacter baumannii and Clostridium diffi  cile. 
Consecutive and retrospective bacterial isolates of the each species/type were collected and 
examined. Th e methods used were conventional multiplex PCR and real-time multiplex PCR. 
Th e typing methods were repetitive PCR (DiversiLab), PFGE (pulsed fi eld gel electrophoresis), 
PCR ribotyping, spa typing, and sequencing-based methods.
During this thesis three usable in-house multiplex PCRs were established for the detection of 
MRSA, carbapenemase genes, and virulence genes in C. diffi  cile.  Th e repetitive PCR method, 
DiversiLab, was found to be a fast and proprietary typing method, very benefi cial in the fi rst-line 
identifi cation of outbreaks. In addition, the Diversilab system may be used in the comparison 
of resistant bacterial isolates. Th e method produced better results with Gram-negatives (ESBL-
producing Enterobacteriaceae and A. baumannii). However, the reference methods still serve 
their purpose in global isolate comparison. In the future, whole genome sequencing will, 
however, most likely replace contemporary typing methods.
TIIVISTELMÄ
Sairaalainfektioita aiheuttavat sairaalabakteerit ovat lisääntyneet viime aikoina. Matkailijat 
tuovat mukanaan entistä resistentimpiä bakteerikantoja omiin sairaaloihimme sairaalasiirtojen 
yhteydessä. Tämä haaste on uusi ja ongelmallinen myös bakteereita tunnistaville laboratoriolle. 
Tarvitaan tarpeeksi spesifi siä ja nopeita työkaluja tunnistamaan ja kartoittamaan nämä 
mikrobilääkkeille resistentit bakteerikannat, jotta estetään näiden kantojen leviäminen omissa 
sairaaloissamme mahdollisimman tehokkaasti.
Tämä väitöskirjatutkimus käsittelee tärkeimpien sairaalabakteerien entistä nopeampaa virulenssi- 
ja resistenssigeenien tunnistamista, sekä bakteerikantojen molekyylibiologista tyypittämistä 
keskussairaalatasolla. Tutkimuksen tarkoituksena oli pystyttää rutiinikäyttöön sairaalabakteerien 
tutkimiseen tarkoitettuja nopeampia virulenssi- ja resistenssigeenejä tunnistavia ns. multiplex-
PCR-menetelmiä. Lisäksi tarkoituksena oli tutkia uusien ja nopeampien tyypittämismenetelmien 
toimivuutta ja käytettävyyttä vanhoihin standardimenetelmiin verrattuna. Samalla tutkimus 
antaa kuvan viime vuosien tilanteesta Helsingin ja Uudenmaan sairaanhoitopiirin alueella 
esiintyvistä sairaalabakteerikannoista.
Tutkimus koostuu kuudesta osajulkaisusta, joissa käsitellään neljän eri bakteerilajin tai 
-tyypin aineistoja. Bakteerit ovat MRSA (metisilliinille resistentti Staphylococcus aureus), 
enterobakteerien kannat, jotka muodostavat ESBL-entsyymejä (Extended Spectrum Beta-
Lactamase), Acinetobacter baumannii ja Clostridium diffi  cile. Kustakin lajista ja tyypistä oli 
kerätty peräkkäisiä (konsekutiivisiä) sekä takautuvia sairaalabakteerikantoja. Tutkimuksessa 
käytettiin erilaisia PCR-menetelmiä, kuten konventionaalinen ja reaaliaikainen multiplex-
PCR.  Tyypitysmenetelminä käytettiin kaupallista DiversiLab-menetelmää (repetitiivinen PCR), 
PFGE (pulssikenttäelektroforeesi)-menetelmää, PCR-ribotyypitystä, spa-tyypitystä ja erilaisia 
sekvensointiin perustuvia tyypitysmenetelmiä. 
Väitöskirjatyön aikana pystytettiin kolme erilaista multiplex-PCR menetelmää, joiden avulla 
edelleen tunnistetaan MRSA, karbapenemaasien tuottogeenejä sekä C. diffi  cilen virulenssigeenejä. 
Repetetiivisellä PCR menetelmällä tehdyissä tutkimuksissa havaintomme oli, että kaupallinen 
nopeampi bakteerien tyypitysmenetelmä, DiversiLab, voisi olla hyödyksi kantojen vertailussa. 
Näin voitaisiin saada lisäarvoa epidemioiden ja niitä aiheuttavien bakteerikloonien nopeaan 
ensilinjan tunnistamiseen, varsinkin gramnegatiivisten bakteerien, kuten ESBL:n ja A. 
baumanniin kohdalla. Perinteisemmillä menetelmillä, kuten PFGE, on vielä toistaiseksi 
paikkansa kansainvälisessä kantavertailussa. Tulevaisuudessa kantojen kokogenomisekvensointi 
tullee kuitenkin syrjäyttämään tämänhetkisiä tyypitysmenetelmiä.
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1.  REVIEW OF THE LITERATURE
1.1  Healthcare-associated infecƟ ons and outbreaks
Th e microbial pathogens that cause healthcare-associated infections (HAIs) have two special 
properties: fi rstly, they are recognized as hospital pathogens, secondly, they have an innate 
ability to survive on surfaces in the hospital environment for long periods of time 1. Th e hospital 
environment provides an important ecological niche for organisms that could have clinical 
signifi cance. Hospitals house large numbers of severely ill patients, oft en with impaired immunity. 
Patients usually undergo many medical procedures bypassing the body´s natural protective 
barriers (e.g. surgery, catheter placement). Medical staff  are moving from patient to patient 
providing the way for pathogens to spread 2. Hospital organisms also tend to be more resistant 
to antibiotics 3. Bacteria may manifest resistance to antibacterial drugs through a vast variety of 
mechanisms. Some species are innately resistant to one or more classes of antimicrobial agents. 
On the other hand, the acquired resistance occurs via several diff erent mechanisms. Th e organism 
may acquire genes encoding enzymes, such as β-lactamases, that destroy the antibacterial agent, 
or effl  ux pumps that extrude the antibacterial agent from the cell. Bacteria may also acquire 
several genes for a metabolic pathway which produces an altered bacterial cell wall, or another 
target, that no longer contains the binding site for the antimicrobial agent. Bacteria also undergo 
mutations that limit the access of antimicrobial agents to the intracellular target site. Bacterial 
resistance may develop vertically as a result of chromosomal mutation followed by selection 
under antibiotic selective pressure. Bacterial resistance may also develop horizontally when a 
susceptible bacterial cell acquires resistance factors from a resistant strain through genetic 
exchange, like conjugation, transformation or transduction. Th is horizontal evolution can occur 
between strains of the same species, or between diff erent bacterial species or even genera 4. It has 
long been known that there is a relationship between antibiotic consumption and resistance, but 
antibiotic usage is also associated with resistance profi les of organisms isolated from fl oors and 
other surfaces within a defi ned local environment. Wards or units that are constantly exposed to 
antibiotics are more likely to harbor resistant micro-organisms 3. Resistant bacteria are spreading 
and becoming severe problems to control, not only within healthcare institutions, but in the 
community as well.
HAIs and the worldwide increasing prevalence of multidrug-resistant organisms (MDROs) 
pose an extraordinary challenge to healthcare systems. Th e role of screening should be better 
assessed and, in many instances, acknowledged, regarding the burden and fi nancial cost for 
healthcare institutions 5. Infectious disease surveillance data are principally used to establish a 
baseline or reference point for the detection of outbreaks requiring immediate investigation and 
intervention. Th e aim of surveillance is to identify problems on an endemic level and surveillance 
produces baseline data that are useful in confi rming the presence of outbreak. Th e purpose 
of outbreak investigations is to track a common source and identify specifi c clusters and risk 
factors 2. Increasing numbers of outbreaks caused by HAIs have generated much attention over 
the last decade. In the future, the utilization of whole-genome sequencing in outbreak analysis 
might facilitate the rapid and accurate identifi cation of virulence factors of the pathogen and be 
used to identify the path of disease transmission within the population and provide information 
on the probable source 6.
Review of the Literature
12
Th e public has associated the visual experience of dirty hospitals with the risk of HAI, but there 
is little evidence to support this at present 1. Hand hygiene and, more specifi cally, use of hand 
rubs (today generally alcohol-based), is the most important means of standard precautions to 
prevent HAIs and transmission of multidrug-resistant bacteria 7, 8. Th e ubiquitous environmental 
contamination by micro-organisms poses an additional risk, however, since the personal 
belongings of the patient and nearby surfaces are oft en contaminated with pathogens, including 
MDROs. When these surfaces are touched by healthcare staff , pathogens may be transmitted to 
patients. Th is is more likely, if the hand hygiene compliance is low 9. Th e impact of environmental 
contamination on HAI and the cost-eff ectiveness of surface disinfection, as opposed to 
detergent-based cleaning, remains a scientifi cally unresolved issue, despite a growing body of 
literature 1, 10, 11.
Since no scientifi c standards have been presented to measure the eff ect of an individual cleaner, 
or to assess environmental cleanliness, fi nding the evidence for a benefi cial outcome in the 
control of infection is further complicated. Th e organisms that cause infection are invisible to 
the naked eye and their existence is not necessarily associated with the presence of visual dirt. 
Recently, tests for detecting the presence of adenosine triphosphate (ATP) as a proxy of microbial 
contamination have been increasing in popularity 12. Sites that are frequently touched by hand 
are thought to provide the greatest risk for patients, and the people in the immediate vicinity of 
the patients provide the most prominent risk.  Th e responsibility for cleaning the sites near the 
patient which are touched by hand does not always rest with the ward cleaner, however, since 
beds, drip stands, lockers and over bed tables may also be cleaned by nurses. Th is overlapping 
responsibility may create confusion and it may lead to cleaning opportunities of some items 
being missed or even abandonend 1, 13.
A broad consensus exists that high standards are essential in hospital cleaning. It is apparent that 
the interior and equipment in patient rooms diff er greatly between European countries. Further 
investment is necessary to engage more well-trained staff  and to improve hospital architecture in 
many countries, but as this is cost consuming, it is unlikely to be accomplished in many hospitals. 
However, as expected, the savings gained by low prevalence of HAI caused by MDROs may well 
outweigh such costs 11.
Surveillance, including feedback, is a crucial part of infection control activities. Th e centers for 
disease control and prevention (CDC) plays a pivotal role in ensuring that state and local public 
health systems are prepared for public health emergencies due to its unique abilities to respond 
to infectious, occupational, or environmental incidents that aff ect the health of the public. Th e 
Finnish National Institute for Health and Welfare (THL) has made out the standard precautions 
for preventing the speed of multidrug-resistant (MDR) bacteria in Finland 14. Th e Finnish 
Hospital Infection Programme (SIRO, established in 1999), has been focusing on the prevention 
and surveillance of healthcare-associated infections and provides services for the investigation of 
hospital outbreaks 15. 
1.1.1  Persistence of HAI pathogens
Inanimate surfaces have oft en been described as the source for outbreaks of nosocomial 
infections. Most Gram-positive bacteria, such as Staphylococcus aureus, including methicillin-
Review of the Literature
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resistant Staphylococcus aureus (MRSA), survive months on dry surfaces (7 days to 7 months). 
Many Gram-negative species, such as Acinetobacter spp. (3 days to 5 months), Escherichia coli 
(1.5 hours to 16 months) and Klebsiella spp. (2 hours to >30 months), are survivors, too. In 
addition, spore-forming bacteria, including Clostridium diffi  cile, can survive up to fi ve months. 
Humid conditions improve persistence for most types of bacteria. Only S. aureus was found 
to persist longer at low humidity 16.  In hospitals, surfaces experiencing hand contact are oft en 
contaminated with nosocomial pathogens and may serve as vectors for cross transmission 17-19. 
Transmission to hands is most successful with E. coli and S. aureus 20 and the main route of 
transmission is via the transiently contaminated hands of healthcare workers. An outbreak of 
HAIs caused by Acinetobacter baumannii in an intensive care unit may serve as an example 21-23. 
During outbreaks, the environment may play a signifi cant role in the transmission of nosocomial 
pathogens, as suggested by observational evidence 13, 16. Th is has been described for various 
types of microorganisms, such as A. baumannii, C. diffi  cile and MRSA. However, the evidence 
to support a role of environmental correlation is not equally strong for all types of nosocomial 
pathogens. For C. diffi  cile and MRSA correlation is stronger than for other pathogens such as A. 
baumannii 24. Th e role of surface disinfection for the control of nosocomial pathogens has been a 
contentious issue for some time. Disinfection of surfaces, however, has been described to reduce 
the acquistion of nosocomial pathogens, such as A. baumannii. It is therefore advisable to control 
the spread of nosocomial pathogens at least in the direct inanimate environment of the patient 
by routine surface disinfection 13, 16.
Multi-resistant Gram-positive bacteria have been reported to be detected in the inanimate 
environment signifi cantly more frequently than Gram-negative pathogens 24. Traditional sites for 
Gram-negative microbes in hospitals have been those constantly or intermittently exposed to 
water. Th ese include hand-wash basins, sinks, sluices, showers, baths and toilets. Bacterial biofi lm 
builds up in plumbing components including taps, water fi lters and sink traps underneath water 
outlets. In addition, bacteria within the biofi lm may display greater capacity for antimicrobial 
resistance, and tolerate chlorine or other disinfectants 25.
For patients harboring multi-resistant Gram-positive bacteria, strict contact isolation in a single 
room as outlined in the guidelines should be performed. For patients with multi-resistant Gram-
negative pathogens, barrier precautions are necessary only for close contact, and a single room 
does not seem to be of benefi t 24.
1.1.2  Costs and benefi ts of prevenƟ on of HAIs
HAIs account for a large proportion of the impairments caused by health care and are associated 
with high costs. In the USA, additional annual costs associated with infections caused by 
resistant organisms, as compared to susceptible organisms, are estimated between 21 billion and 
34 billion dollars and more than 8 million additional hospital days 26. In Europe health care and 
productivity costs are estimated to be more than 1,5 billion euros per year, while costs in the 
USA are estimated to be 55 billion dollars 27. In the EU, MRSA infections have been estimated 
to result in 1 million extra days of hospitalization and an attributable additional hospital cost of 
380 million euros annually 28. Better evaluation of the costs of these infections could motivate 
health care administrators and payers to justify investing in prevention and in necessary systems 
to decrease these infections 29. For example, MRSA search and destroy policy in a country with 
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low endemic MRSA incidence saves money and lives. In countries that did not implement the 
proposed policy, the number of cases of MRSA bacteremia increased 11. Among C. diffi  cile, 
elimination of within-ward transmission by improving sanitation and reducing the average 
length of stay (from six to three days) resulted in the most potent symptomatic infection control 
combination, cutting rates down from three to less than one per 1000 hospital bed days 30. It has 
been estimated that the rate of HAI per 1000 patient days has increased by 36 % from 1975 to 
1995 31. Estimating the economic burden of antibiotic-resistant bacterial infections still remains 
a challenge, due to variability in diff erent studies 27.
Th e more recent concern is the carbapenem-resistant Enterobacteriaceae, which are increasingly 
reported worldwide and have gained substantionally more attention to prevention around the 
world 32-34. With rapid diagnostic techniques and strict implementation of hygiene measures it is 
possible to control their spread in hospital settings 35.
1.2  Methicillin-resistant Staphylococcus aureus (MRSA)
S. aureus is a human pathogen, but also found among animals such as livestock, wildlife and 
companion animals, and it causes both nosocomial and community-acquired (CA) infections. 
S. aureus can cause a wide variety of diseases, such as pneumonia, mastitis, osteomyelitis, 
endocarditis, skin infections, abscesses, food poisoning, toxic shock syndrome and septicemia 36. 
S. aureus is a leading cause of bacteremia and endocarditis and is associated with high morbidity 
and mortality 37. S. aureus can express an extensive number of diff erent virulence factors, 
playing a role in the pathogenesis of infection. A virulence factor may have several functions 
in pathogenesis, and multiple virulence factors may perform the same function. Th ree 
classes of factors are involved in pathogenesis: surface proteins (e.g. staphylococcal protein 
A, Spa), secreted proteins, including superantigens (e.g. toxic shock syndrome toxin TSST-
1), cytotoxins (e.g. Panton-Valentine leukocidin, PVL), and cell-surface-bound proteins 38. 
MRSA is epidemiologically the most important resistant Gram-positive pathogen. It can cause 
fatal infections especially to patients of old age and/or underlying disease 39-41. HA- CA-, and 
LA-MRSA has spread worldwide during the last 70 years and continues to be a growing burden 
for human and animal healthcare systems as well 42.
In 1942, 2 years aft er the introduction of penicillin for medical use, the fi rst penicillin-resistant 
S. aureus was observed. In addition, S. aureus developed methicillin-resistance due to the 
acquisition of the mecA gene in 1961, two years aft er the introduction of methicillin. Th e mecA 
gene, coding for the 78-kDA penicillin-binding protein (PBP) 2a (or PBP2´), causes resistance to 
methicillin and most other β-lactam antibiotics with only a few exceptions (e.g. ceft obiprole and 
ceft aroline). In methicillin-susceptible S. aureus (MSSA) strains the β-lactam antibiotics bind 
to the native PBPs that are present in the cell wall and inhibit the synthesis of the peptidoglycan 
layer. Th is results in the death of the bacterium.  In MRSA the β-lactam antibiotics cannot bind to 
its target 43. Th e mecA gene is regulated by the repressor MecI and the trans-membrane β-lactam-
sensing signal-transducer MecR1 44. Th e mecA gene (2,1 kb) is located on a mobile genomic 
island called staphylococcal cassette chromosome mec (SCCmec) 45. Th e origin of SCCmec is 
not known. It is considered to have originated from other bacterial species, and subsequently 
integrated into the chromosome of S. aureus through the horizontal transfer of the mecA gene 43. 
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SCCmec is a 21-67 kb fragment present at a specifi c attachment site (attBscc) in the chromosome 
of S. aureus. Th e site attBscc is found in an open reading frame (ORF) of unknown function, 
designated orfX. In addition, SCCmec consists of the mec complex, cassette chromosome 
recombinase (ccr) complex, joining regions (J), as well as of repeated 15 bp core sequences at 
both ends 45, 46. To date, eleven diff erent types of SCCmecs have been identifi ed in S. aureus, 
all defi ned by the combination of the ccr gene complex and the class of mec gene complex 47. 
SCCmec types I, IV, V, VI, and VII mainly cause β-lactam resistance, while SCCmec types II and 
III cause multiresistance due to additional drug resistance genes integrated into SCCmec 43. In 
general, SCCmec types I, II and III are involved in hospital-acquired MRSA (HA-MRSA) isolates 
and SCCmec types IV, V and VII in community-acquired MRSA (CA-MRSA) isolates 48. In 
addition, a strong epidemiological association has been found between PVL and the emergence 
of CA-MRSA. PVL strains seem to be particularly prone to cause disease in the community, 
in association with the methicillin chromosomal gene cassette SCCmec type IVa 49–51. However, 
the distinction between CA-MRSA and HA-MRSA is becoming increasingly blurred and the 
typical patient at risk for carrying MRSA is more and more diffi  cult to defi ne. It also seems that 
CA-MRSA is spreading from closed risk communities into the general population 52.
In 2007 the novel mecA gene (mecALGA251) was found in England during an epidemiological 
study of bovine mastitis. Similarly to conventional mecA, mecALGA251 is located within a SCCmec 
element inserted into the 3´ region of orfX. Th is novel SCCmec was given the designation type 
XI SCCmec. In 2012 it was renamed mecC. Th e mecC gene encodes the expression of protein 
PBP2c 53–55. MecC MRSA strains have now been isolated in small numbers from humans and 
a wide range of other host species in several European countries 53, 54. Th e fi rst report of bovine 
MRSA carrying mecC in Finland was in 2013 56, and in same year three MRSA strains with the 
mecC gene were isolated from clinical samples in the hospital district of Helsinki and Uusimaa, 
Pirkanmaa and North Savo. Two of the strains were of the spa type t843 and one of the spa type 
t742 57.
In 1997, the fi rst clinical strain of MRSA with reduced susceptibility to vancomycin (MIC 8 
mg/L) was found in Japan 58. Th e mechanism of vancomycin intermediate-resistant S. aureus 
(VISA) strains is mediated by mutations and altered expression of genes resulting in a thickened 
cell wall that prevents the functioning of vancomycin. More strains with similar levels of 
vancomycin resistance have subsequently also been isolated in other countries 59. Th e fi rst case of 
vancomycin-resistant S. aureus (VRSA) was found in 2002 in Michigan, USA 60. Since then only 
few isolates have been encountered.
1.2.1  MRSA carriage and prevalence
S. aureus is both a pathogen and a commensal organism. S. aureus colonizes the skin and mucosal 
surfaces of humans. Th ree types of S. aureus nasal carriers have been historically distinguished: 
persistent carriers (20 %), intermittent carriers (30 %) and non-carriers (50 %) 61. Later it 
was proposed that there are only two types of nasal carriers: persistant carriers and others 62. 
Th e most common S. aureus carriage sites are the nose, skin, throat and, possibly, the gastro-
intestinal tract. Colonization provides a reservoir from which bacteria can be introduced when 
host defenses are breached and it clearly increases the risk for subsequent infection. Colonization 
also allows S. aureus to be transmitted among individuals in both health care and community 
settings 61.
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MRSA is one of the most frequent causative agents of antibiotic-resistant HAIs worldwide. 
Intensive care units and burn units characteristically have higher rates, because of high antibiotic 
usage and a high number of vulnerable patients 39, 63. MRSA prevalence varies strongly between 
countries and between diff erent regions and hospitals. In Europe, MRSA percentages range 
from under 1 % (Norway) to over 60 % (Romania). Fortunately, the percentage of invasive 
MRSA isolates in Finland in 2013 was only 1,7 % 64, 65. Finland has been a country of low MRSA 
incidence for a long time 65, 66 even though isolated MRSA outbreaks have been published 67.
Th e major HA-MRSA clones are the clonal complex CC5, CC8, CC22, CC30 CC45 or the 
sequence type ST239 68. Th e distribution of HA-MRSA clones varies geographically and oft en 
respects geographical borders. ST239 is successful in Asia and South America and has caused 
hospital outbreaks for a short period in the UK 69, but did not become established and had almost 
disappeared by 2006. CC22 has become the dominant HA-MRSA clone in the UK 70. Invasive 
MRSA clones in Europe display a typical epidemic behavior and have a predominantly regional 
distribution. Th e most frequent spa types in Europe are t032 (UK, Ireland, Portugal, Germany and 
Hungary), t008 (Belgium and France), t041 (Croatia, Slovenia and Italy), t003 (Czech Republic), 
t002 (Greece) and t067 (Spain). Th e most frequent sequence type is ST22 71. ST22 has a broad 
host range and behaves as a nosocomial pathogen within a veterinary health-care setting just as 
it does within human hospitals 72. USA300 (ST8) is a virulent and easily transmissible strain of 
MRSA. It is the predominant community-associated MRSA clone in the United States 73, 74. It is 
also increasingly seen in Europe 75. MRSA belonging to ST398 has emerged in several European 
countries and is regarded as being a livestock-associated (LA) MRSA 71, 76. According to the data 
from THL, 1417 MRSA cases were found in Finland in 2014 and 35 % of them were from the 
district of Helsinki and Uusimaa (Figure 1) 77. In 2013, the most common spa types in Finland 
were t172, t067, t008, t032 and t044 57. 
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Figure 1. MRSA cases in Finland between 1995 and 2014. 
Source: THL 77.
1.2.2  IdenƟ fi caƟ on of MRSA
Although methicillin is no longer produced as an antibiotic for human therapy, the name MRSA 
has persisted and can be regarded as referring to resistance to virtually all β-lactam antibiotics. 
Susceptibility testing now typically uses oxacillin and/or cefoxitin. Th e minimum inhibitory 
concentrations (MICs) of oxacillin for MRSA strains vary from apparently sensitive levels to 
those of >256 μg/ml. Cefoxitin has generally been accepted as a potent up-regulating agent of 
mecA expression and has been used in selective media for the isolation of MRSA, as well as in 
screening methicillin-resistance in staphylococci 44, 78.
Several rapid MRSA-PCR-methods, both in-house and commercial, targeting S. aureus-specifi c 
genes e.g. femB, femA, nuc or coa in combination with mecA have been described 79-85. To 
facilitate the rapid detection of colonized patients, commercial real-time PCR assays have been 
developed 85. Th e fi rst method to directly detect MRSA from clinical specimens was developed 
by Huletsky et al. 86 and it became commercially available as the IDI-MRSATM assay. Th is method 
was based on specifi c amplifi cation products at the junction of the right extremity sequence of 
the staphylococcal cassette chromosome (SCCmec) and the chromosomal orfX gene sequences 
of S. aureus located to the right of the SCCmec integration site 86. Th e principle of this method 
is used in two commercially available tests, the BD GeneOhm MRSA assay (BDGO) (BD, San 
Diego, CA, USA) and the Xpert MRSA assay (Cepheid, Inc., Sunnyvale, CA, USA). Th ese tests 
are very eff ective in identifying the negative samples, but for PCR positive samples back-up 
cultures may be useful 85, 87.
Review of the Literature
62 36 61 83 111 77 77 102
231
634
447
365 295 363 290 321 336
373 389
485
27 72 59
106 100 184
267
495
582
840
930
952 1028
1416
970 978
1031 939 923
932
0
200
400
600
800
1000
1200
1400
1600
1800
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
N
um
be
ro
f?c
as
es
Year
The?rest?of?Finland
The?district?of?Helsinki?and?Uusimaa
18
1.3  Extended spectrum β-lactamase (ESBL) producing 
 Enterobacteriaceae strains 
Members belonging to the family Enterobacteriaceae are widely distributed throughout the 
environment and many species are commonly recognized pathogens and consistently seen in 
health care-associated infections 88. Enterobacteriaceae is one of the most important groups 
causing a wide range of diseases. Th ese bacteria infect the urinary tract, respiratory tract, and 
can cause bloodstream infections. Th ey form a large potential reservoir for resistant genes 
between diff erent family members. Escherichia coli and Klebsiella pneumoniae are the clinically 
most important Gram-negative bacteria that cause serious infections. From all Gram-negative 
bacteremias the proportion of E. coli and K. pneumoniae is 75-87 % in community-acquired and 
62-64 % in health care-associated infections 89, 90.
Many resistant genes are shared by diff erent species of Enterobacteriaceae, but also a multitude 
of diff erent resistance genes or variations of existing features have developed 91. Potential 
interconnections exist between the resistomes of soil, the human gastrointestinal tract, and 
clinical pathogens. Transmission from soil to clinic establishes soil as a direct source of 
pathogenic resistance genes 92.  Th is increasing resistance has culminated with the emergence of 
panresistant strains for which there are no therapeutic options 88. ESBL production is the major 
cause of clinical cephalosporin resistance in Enterobacteriaceae and has become particularly 
prominent, not only in nosocomial but also in community-onset Enterobacteriaceae infections 
worldwide 93. ESBLs have been reported most frequently in Escherichia coli and Klebsiella species. 
Th ey have been found in other bacterial species as well, including Salmonella enterica, Proteus 
mirabilis and Serratia marcescens 94.
Th ere are two major strategies which Enterobacteriaceae have adopted. Th e acquisition and 
evolution of ESBLs: 1) single or multiple amino-acid substitution at a critical position causing 
extended substrate specifi city of existing β-lactamases, and 2) capture, stabilization, and spread 
of new genetic element encoding new enzymes with ESBL activity 95. As mentioned before, ESBLs 
are found both in the nosocomial settings and in the community, and Escherichia coli has become 
dominant among the ESBL-producing enterobacterial species. Th is is especially disturbing as 
the human gut carriage of E. coli favors the dissemination of ESBLs in the community 96. Also 
of concern is that ESBLs oft en show multiple coresistance 97. In hospitals, patients with serious 
underlying diseases, prolonged stay, prior antibiotic use and invasive medical devices are at high 
risk for ESBL colonization and infection 94, 98. 
1.3.1  β-lactamases
Th e production of β-lactamases is the predominant cause of resistance to β-lactam antibiotics in 
Gram-negative bacteria. Th ese enzymes cleave the amide bond in the β-lactam ring, rendering 
β-lactam antibiotics, including third generation cephalosporins. Generally ESBLs are inhibited 
by clavulanic acid, sulbactam and tazobactam 98, 99. 
Th ere are diff erent schemes for the classifi cation of β-lactamases, like Ambler Classes 100 and 
Bush Groups 101 (Table 1). Th e Bush Groups 1 through 3, base on the substrate and inhibitor 
profi le. Th e Ambler classifi cation divides enzymes into four classes (A to D) on the basis 
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of their amino acid sequences. Classes A and C are the most frequent 102. Classes A, C and D 
include enzymes that hydrolyze their substrates by forming an acyl enzyme through an active 
site (serine). Th ey are known as serine β-lactamases. Class B β-lactamases are metalloenzymes 
that utilize at least one active-site zinc ion to facilitate β-lactam hydrolysis. Th ese are known as 
metallo-β-lactamases (MBLs) 103. 
1.3.2  ESBL enzymes
Th e spread of extended spectrum β-lactamase-producing Enterobacteriaceae strains is an 
ongoing concern in health care 93, 98, and more than 350 diff erent (at 2010) ESBLs have been 
identifi ed 95, 107. Th e classifi cation of ESBLs is complex, as so many enzymes are responsible, 
the most prevalent being CTX-M 25. In addition, as new ESBL enzymes are being found, the 
redefi nition of extended spectrum β-lactamase has been suggested in the Nordic countries 108, 109.
Th e majority of ESBLs are from the TEM, SHV and CTX-M families and are classifi ed into class 
A. Th e fi rst TEM-1 enzyme was identifi ed in 1965 in Greece. For decades TEM (TEM-1 and 
TEM-2) and SHV used to be the main enzymes in class A 110. Th ese enzymes are usually located 
in a plasmid. Plasmids can easily be transmitted into diff erent bacterial cells, causing rapid 
resistance. Some of the class A enzymes hydrolyze penicillins, fi rst, second and third generation 
cephalosporins, as well as monobactams 111.
Th e CTX-M enzymes (belonging to class A) arose by plasmid transfer from preexisting 
chromosomal ESBL genes from Kluyvera spp. by mobile elements (such as insertion sequence 
ISEcp1). ISEcp1 plays an important role in the expression and continuous spread of these 
β-lactamases. Today the CTX-M enzymes have superseded the TEM and SHV ESBLs 102, 112. 
Currently as many as 172 CTX-M alleles have been identifi ed 107, 113. Th e CTX-M β-lactamase 
carries 291 amino acid residues and the change in any one of them results in a new CTX-M 
variant 95. Th e fi rst CTX-M was detected in a clinical E. coli isolate in 1990, and was named aft er 
its higher hydrolytic activity against cefotaxime than ceft azidime, and the place of fi rst isolation 
(Munich, Germany) 114. Since 2000, CTX-M-producing Enterobacteriaceae have been globally 
detected. CTX-M-genes have become widespread and represent a threat to the treatment of 
infections in the community as well as in hospitals 93, 95, 115. 
Th e CTX-M types belong to the molecular class A or functional group 2be-lactamases and 
include at least six major lineages (i.e., CTX-M-1-like, CTX-M-2-like, CTX-M-8-like, CTX-
M-9-like, CTX-M-25-like, and KLUC-like) based on amino acid sequence similarities 91, 102. 
CTX-M-15 is the most widely distributed CTX-M. It was fi rst detected in E. coli isolated from 
India in 2001. CTX-M-15 belongs to the CTX-M-1 cluster and has oft en been associated with 
co-production of other β-lactamases. Th e successful spread of E. coli producing CTX-M-15 is 
due to the spread of an epidemic clone with selective advantages (such as multiple antibiotic 
resistance and enhanced virulence factors) between hospitals, long-term care facilities and the 
community, or the horizontal transfer of plasmids or genes that carry blaCTX-M-15 alleles 112.  Th e 
worldwide spread of the CTX-M-15 is mainly driven by two endemic E. coli strains belonging 
to phylogroups B2 and D, which are known to be associated with the hospital settings and 
extraintestinally pathogenic E. coli. Th e dissemination of E. coli CTX-M-15 phylogroup B2 
strain corresponds to the sequence type 131 (ST131) that was responsible for several clonal 
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outbreaks 116. Th e multidrug resistant clone ST131 (serogroup O25b) is a pandemic clone, 
predominantly causing community-related infections and rapidly emerging all over the globe 117. 
Th e understanding from the various reports is that CTX-M-15 and CTX-M-14 (in the Western 
Pacifi c region) are the most important types posing a threat to human and animal health 113. 
ß-lactamase inhibitors are eff ective in vitro against class A β-lactamases including CTX-M, TEM 
and SHV. Th ey are the agents that inhibit the β-lactamase enzyme by irreversible binding to its 
active site, thus rendering it permanently inactive. Th e fi rst clinically used β-lactamase inhibitor 
was clavulanic acid (isolated from Streptomyces clavuligaris). It has a weak antimicrobial 
activity, but if combined with amoxicillin, it signifi cantly increases the antimicrobial activity 
of amoxicillin. Th e other ß-Lactamase inhibitors such as sulbactam, tazobactam or avibactam 
are combined with other β-lactamases, such as ampicillin, piperacillin, ceft azidime, and 
ceft aroline 111.
1.3.3  ESBL carriage and prevalence
Th e digestive tract is the main reservoir from which enterobacteria originate both in community-
acquired and hospital-acquired infections. Th e fi rst faecal carriage of an ESBL- Enterobacteriaceae 
strain in the community was reported in Spain in 2001 118. Before 2008, the reported rates of 
ESBL carriage in the community were almost always under 10 %, but aft er 2008 carriage rates 
increased in some parts of Southeast Asia exceeding 50 % 113. Traveling plays an important role in 
the disseminating ESBL strains. E. coli CTX-M-15 producing ST131 clone is dominant in persons 
returning from the Indian subcontinent, Europe, and the Middle East, CTX-M-14 producing 
strains in persons returning from East Asia 95, 119. Such acquisition can be achieved even without 
hospitalization or contact with the health care system in the visited country 119. Traveling in 
highly endemic areas, such as India, has been associated with colonization 120, 121. In a recent 
Finnish study where 430 travelers were examined aft er traveling outside Scandinavia, it was 
found out that 21 % of the travelers became colonized with ESBL. Th e occurrence of traveler´s 
diarrhea and the use of antimicrobials raised the risk up to 80 %, but the risk factors proved to 
be independent. In this study, the area of highest risk was South Asia 122. Th e acquisition rate 
of multidrug-resistant Enterobacteriaceae is higher in Asia than in sub-Saharan Africa or Latin 
America, and carriage lasts longer in travelers returning from Asia 123.
In the recent years we have found approximately one thousand new clinical cases per year in 
the district of Helsinki and Uusimaa (Figure 2) when screening samples have been excluded. 
According to data from the National Institute for Health and Welfare in 2014 approx. 4500 ESBL 
carriers were found in Finland and more than 90 % of them were E. coli strains 77. One third of all 
cases were from the district of Helsinki and Uusimaa. 
Review of the Literature
22
Figure 2. ESBL producing Enterobacteriaceae isolates in the district of Helsinki and Uusimaa 
(HUSLAB) material between 2004 and 2014. (Th e fi rst isolate only, screening excluded)
1.3.4  IdenƟ fi caƟ on of ESBLs
Th e identifi cation of ESBL-producing Enterobacteriaceae is challenging, and there are several 
methods for the laboratory to choose from. Both phenotypic and genotypic methods are available 
for the detection of ESBLs 94, 98.
Several selective culture media agar, supplemented with cefotaxime and/or ceft azidime at various 
concentrations, have been proposed for the detection of ESBL producers. Also a commercial 
selective chromogenic agar medium (e.g. chromID ESBL) has been developed for the detection 
of ESBLs. Th e chromID ESBL uses cefpodoxime as a substrate contrary to the previously used 
ceft azidime or cefotaxime. Th is was noted to increase sensitivity 124. ESBL screening and detection 
can be performed by double disk approximation or the double disk synergy method, using 
combination disks or microdilution. Confi rmation can be achieved using MIC broth dilution, 
the Etest or an automated instrument (e.g. Vitek). Molecular methods are available as well, such 
as PCR, DNA probes and restriction fragment-length polymorphism (RFLP) 94. 
Several typing methodologies are available in characterizing E. coli and K. pneumoniae in 
epidemic situations, the most widely used of which is PFGE. Other methods include several 
repPCRs and MLST 125.  Today the accessibility of whole genome sequencing (WGS) presents the 
opportunity for national reference laboratories to provide understanding of the epidemiology 
and pathogenicity of bacteria that are a threat to public health. WGS has a huge potential in both 
diagnostics and routine surveillance 126.
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Screening for ESBL carriage is systematic in many hospitals. Th e cornerstone of diagnosing 
ESBL is a reliable phenotypic screening and confi rmatory method. In addition, a reliable and 
rapid typing method for the detection of internationally spread ESBL clones, as well as for the 
identifi cation of outbreaks, is needed 93. Once identifi ed, ESBL carriers are in most cases isolated 
in single rooms, where contact precautions are recommended to prevent cross-transmission. 
However there is wide variation, even within a single geographical area, in infection control 
strategies to contain or control ESBL-PE and carbapenemase producing Enterobacteriaceae 
(CPE) 127 and the eff ectiveness is debatable 128. At present, systematic screening for ESBL carriage 
upon admission to hospital is not recommended, because it is costly and its effi  ciency has not 
been demonstrated 113.
Infections, such as blood stream infections due to Escherichia coli and other Enterobacteriaceae 
have become more prevalent, along with increasing antibiotic resistance. Traditionally, β-lactam 
antibiotics have been used, but currently more strains demonstrate the presence of extended-
spectrum beta-lactamases (ESBLs) which confer resistance to penicillins, as well as to most 
cephalosporins, with the exception of cephamycins. Th e genes responsible for the production of 
these enzymes among Enterobacteriaceae are oft en accompanied by genes mediating resistance 
to other groups of antibiotics, e.g. aminoglycosides and fl uoroquinolones 25. Carbapenems 
are the drugs of choice for life-threatening and severe infections caused by ESBL-producing 
organisms 129. 
Colistin, tigecycline and fosfomycin are eff ective drugs against carbapenem-resistant 
Enterobacteriaceae. Colistin has become the backbone agent in their treatment, typically in 
combination with other antibiotics, despite its nephrotoxicity 130.
1.4  Carbapenemase producing Enterobacteriaceae (CPE)
Carbapenem-resistant Enterobacteriaceae (CREs) or carbapenemase-producing 
Enterobacteriaceae (CPEs) are quite recently encountered challenges. Th eir evolution and spread 
indicate a complex and sophisticated genetic evolution involving transcontinental spread 131. Th e 
fi rst carbapenemase producer in Enterobacteriaceae (NmcA, class A serine carbapenemase) was 
identifi ed in 1993 132. Since then, a large variety of carbapenemases have been found, mostly 
belonging to Ambler classes A and D (serine carbapenemases) as well as class B (metallo-β-
lactamases). In addition, chromosomally encoded Ambler class C (cephalosporinases) may 
possess notable activity toward carbapenems 133. CPEs have the propensity to spread easily 
between humans via hand carriage or contaminated food and water, and acquired genetic material 
spreads through horizontal gene transfer mediated mostly by plasmids and transposons 131, 133. 
Th e emergence of CPE has been described in a number of countries and there are limited options 
for treatment of infections caused by these organisms, hence the importance of infection 
prevention and control measures. Acquisition of drug-resistant Gram-negative bacilli is usually 
associated with admission to a tertiary hospital, but both ESBLs and CPEs can be found outside 
acute hospitals, due to patient carriage to long-term care facilities. Th e international spread of 
these bacteria and their presence in the food chain implies that their prevention and control is a 
greater challenge than that presented by MRSA and C. diffi  cile 131. 
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1.4.1  Class A serine carbapenemases
Class A serine carbapenemases include the non-metallocarbapenemase of class A (NmcA). 
Some are chromosome-encoded, such as NmcA, IMI-1, SME and SFC-1 and others are plasmid-
encoded such as KPC, IMI-2 and GES 133. Members of this group hydrolyze carbapenems as well 
as cephalosporins, penicillins and aztreonam, and are partially inhibited by clavulanic acid in 
vitro 134. Primarily these carbapenemases have been identifi ed in Enterobacter cloacae, Serratia 
marcescens and Klebsiella pneumoniae 111. Klebsiella pneumoniae carbapenemase (KPC) is the 
clinically most common enzyme and KPC producers have spread around the world and caused 
major clinical and public health concerns. Th e fi rst KPC (KPC-2) producer was identifi ed in 
1996, in the United States 135. Up to now there are 24 diff erent KPC variants, all being point-
mutant derivatives of the common amino acid sequence 35, 107. Several hospital outbreaks, most 
oft en due to K. pneumoniae KPC isoenzymes KPC-2 and KPC-3, have been reported, and the 
most predominant clone is K. pneumoniae ST258 91.
1.4.2  Class B metallo-β-lactamases (MBLs)
Class B enzymes are Zn2+ -dependent β-lactamases. Th e hydrolytic mechanism diff ers from 
serine β-lactamases, which have serine at their active site. Organisms producing these enzymes 
hydrolyze all β-lactams except monobactams, such as aztreonam. Th ey are usually resistant to 
all penicillins, cephalosporins, carbapenems and the clinically available β-lactamase inhibitors. 
Th eir activity is inhibited by EDTA but not by clavulanic acid. MBL genes are located in the 
chromosome, plasmid or integrons. Typically Pseudomonas aeruginosa, K. pneumoniae and 
Acinetobacter baumannii produce these metallo β-lactamases encoded by mobile genetic 
elements 111. Th e most common MBLs are VIM (Verona-integron-encoded metallo-β-lactamase), 
IMP and more recently NDM (New Delhi metallo-β-lactamase-1), described fi rst in 2009 in 
a Swedish patient returning from New Delhi 136. Th e fi rst MBL, IMP, (IMP-1) was identifi ed 
in Japan in 1991 in Serratia marcescens 137. Since then MBLs have been reported worldwide, 
VIM being the most common. NDM positive Enterobacteriaceae are now the focus of global 
attention, and NDM producers are being reported in the environment and in the community. 
NDM-1 has been identifi ed mostly in non-clonal E. coli and K. pneumoniae, and many NDM 
producing strains remain susceptible only to tigecycline, colistin and fosfomycin. Up to now 
11 variants of this enzyme have been published and 16 have been assigned, originating mostly 
from Asia 107, 133, 138, 139. NDM-1 has also been identifi ed in E. coli ST 131, a well-known source of 
community infections 140. 
1.4.3  Class C serine cephalosporinases 
Class C AmpC β-lactamases are usually encoded by bla genes located in the bacterial 
chromosome, although plasmid-borne AmpC enzymes are becoming more prevalent. Class C 
β-lactamases include CMY-2, P99, ACT-1 and DHA-1 (Table 1) 103, 141. AmpC producers that 
resist inhibition by clavulanate and sulbactam in vitro, are members of Enterobacteriaceae, 
typically Enterobacter spp. and Citrobacter spp. Instead, Klebsiella spp., Salmonella spp. and 
Proteus mirabilis normally do not harbor chromosomal blaAmpC genes. Organisms expressing 
the AmpC β-lactamase are typically resistant to penicillins, β-lactam-β-lactamase inhibitor 
combinations, and cephalosporins. Production of chromosomal AmpC can be derepressed by 
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induction with certain β-lactams, particularly cefoxitin, which can cause dramatic increase in 
MICs during the course of β-lactam therapy 104, 111.
1.4.4  Class D serine oxacillinases
Class D β-lactamases were initially categorized as “oxacillinases” because of their ability to 
hydrolyze oxacillin. OXA β-lactamases can also confer resistance to penicillins, cephalosporins, 
extended spectrum cephalosporins (OXA-type ESBL) and carbapenems (OXA-type 
carbapenemases). OXA enzymes are typically resistant to inhibition by EDTA as well as by 
clavulanate, sulbactam, and tazobactam, with some exceptions. Interestingly, sodium chloride at 
concentrations of >50 to 75 mM inhibits some carbapenem-hydrolyzing oxacillinases 111. OXA-48 
represents the predominant enzyme isolated around the world, displaying thus far six diff erent 
variants (OXA-48, OXA-162, OXA-163, OXA-181, OXA-204 and OXA-232) 142. Th e fi rst OXA-48 
(from K. pneumoniae) producer was identifi ed in Turkey in 2003 143. OXA-48 enzymes are found 
in multiple species of Enterobacteriaceae and are nowadays frequently observed in E. coli. Th ese 
enzymes are not found in nonfermenters and are not related to the OXA-carbapenemases that 
have been found in Acinetobacter 144. On the other hand, OXA enzymes also include rapidly 
emerging enzymes in A. baumannii, such as OXA-58, OXA-23 and OXA 24/40 111.
1.4.5  Prevalence of CPE
KPC enzymes are currently clinically the most signifi cant enzymes among the class A 
carbapenemases. Endemic areas in Europe are Greece and Italy, and probably Poland. Among 
MBLs, the most common families are VIM and IMP groups together with the emerging NDM 
group 35. In certain areas of Pakistan up to 20 % of the population may carry NDM-1 producers, 
and these organisms have been identifi ed in tap and environmental water of New Delhi. NDM-1 
has also been identifi ed in E. coli sequence type ST131, which is known to effi  ciently mobilize the 
ESBL CTX-M-15 worldwide, as a source of CA-infection 133. Th e carbapenem-hydrolyzing class 
D β-lactamases or oxacillinases, such as OXA-48, are widely disseminated throughout European 
countries 35. Until now, only a few cases of carbapenemase producing Enterobacteriaceae 
have been found in Finland 145, 146. In the HUSLAB material, 53 carbapenemase producing 
Enterobacteriaceae strains were found between 2008 and 2014. Th e fi rst two K. pneumoniae 
KPC-2 strains carrying ST258 were detected in Finland in 2009 147, 148. 
1.4.6  IdenƟ fi caƟ on of CPE
Th e carbapenemase production cannot simply be inferred from the resistance profi le. 
Criteria must be established to discern which isolates should be suspected and screened for 
carbapenemase production, and to advise which tests should be adopted for confi rmation of 
the resistance mechanisms. Th e detection of carbapenemase producers in clinical infections is 
based fi rstly on susceptibility testing results obtained by disk diff usion or by automated systems, 
such as Vitek. However, carbapenem MICs for carbapenemase producers may vary within the 
susceptibility range, as defi ned by either the CLSI or the EUCAST clinical breakpoints 149. 
A number of simple phenotypic tests, such as the modifi ed Hodge test (MHT) and Carba NP, 
have been described for the detection of carbapenemase producers. Most of them base on the 
disc diff usion format. In addition, several inhibitor-based tests have been developed. For the 
specifi c detection of MBL producers, the Etest MBL (bioMérieux, Solna, Sweden) is available. 
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It bases on the inhibition of MBL activity by EDTA. Boronic acid-based inhibition testing 
has been reported to be specifi c for KPC detection in K. pneumoniae when performed with 
imipenem or meropenem 133, 150. Spectrophotometric measurement of carbapenem hydrolysis is 
needed for detecting carbapenemase activity, and it is considered to be the reference standard 
method for the detection of carbapenemase producers. Nowadays the standard for identifi cation 
of carbapenemases is based on the use of molecular techniques, mostly PCR. Real-time PCR 
methods (simplex and multiplex PCRs) are routinely performed for the detection of the 
organisms. Th ere are also commercially available kits based on PCR and hybridization 151. 
Sequencing of PCR products may be of interest, mostly for epidemiologic purposes. 
Th e prevention of the spread of carbapenemase producers relies on the early detection of carriers. 
Screening should include patients who were hospitalized while abroad and then transferred to 
another country, as well as patients at risk, such as immunocompromised patients 133. Unlike with 
MRSA and VRE, there is less agreement about who and when to screen and which identifi cation 
methods to use for multidrug-resistant Enterobacteriaceae, due to the diversity of bacteria 
involved and their resistance mechanisms 25. Th ere is no universal screening medium able to 
detect all types of carbapenemase producers with high sensitivity and high specifi ty. 
1.5  MulƟ drug resistant Acinetobacter baumannii 
Acinetobacters are typical opportunistic pathogens that usually form a threat to critically ill, 
hospitalized patients only. Hospital-acquired Acinetobacter infections comprise of ventilator-
associated pneumonias, bloodstream infections, urinary tract infections, wound infections, skin 
and soft  tissue infections, and secondary meningitis 152. Acinetobacter baumannii, Acinetobacter 
pittii, Acinetobacter nosocomialis and Acinetobacter calcoaceticus are grouped as the Acinetobacter 
calcoaceticus-baumannii complex (ABC) as they are mutually closely related and are diffi  cult to 
distinguish from each other by phenotypic properties 153. While A. calcoaceticus is not associated 
with human infections, A. baumannii, A. pittii and A. nosocomialis have been known to cause 
both CA and HA infections 154.  Among Acinetobacter species, A. baumannii is regarded as one 
of the most common organisms that causes healthcare-associated infections and outbreaks 
worldwide, especially within intensive care units (ICUs) 152, 155. Increased risks of having an 
infection caused by A. baumannii are encountered in a trauma unit (especially war trauma), 
burn unit, and a long-term care facility, particularly a facility caring for ventilator-dependent 
patients, as well as at the ICU. Risk factors for colonization and infection are recent surgery, 
central vascular catheterization, tracheostomy, mechanical ventilation, enteral feeding, and 
treatment with third-generation cephalosporin, fl uoroquinolone, or carbapenem antibiotics 156.
A. baumannii has become endemic in hospitals due to its versatile genetic machinery, which 
allows it to quickly evolve resistance factors, and to its remarkable ability to tolerate harsh 
environments 157. Also reports of CA-Acinetobacter infections have increased over the past 
decade 158. 
A. baumannii is clonal in nature, and molecular typing has shown the existence of three distinct 
clusters (EUI, II and III) from various locations in Europe. Global epidemiology performed by 
using rep-PCR indicates that there are eight worldwide clusters (WW1-8) 155. KPC- and GES-type 
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of class A carbapemases have been described 159, as well as four groups of MBLs: IMP-like, VIM-
like, SIM-like and recently the NDMs 160. It has been strongly suggested that Acinetobacter spp. 
has been a reservoir of NDM genes before being hosted by enterobacterial species. Th ose fi ndings 
highlight that even though A. baumannii is usually recognized as a fi nal acceptor for resistant 
genes, it may acquire several resistance determinants and transfer them to Enterobacteriaceae 
and Pseudomonas spp. 138.
Th e class D carbapenemases are by far the most prevalent carbapenemases in A. baumannii and 
they can be grouped into six subclasses: intrinsic chromosomal OXA-51-like, the acquired OXA-
23-like, OXA-24/40-like, OXA-58-like, OXA 143-like and OXA-235-like 160. Th e fi rst OXA-type 
enzyme (OXA-23) in A. baumannii was detected in 1985 in Scotland 161. Th e emergence and 
spread of several outbreaks or sporadic A. baumannii strains producing OXA-23-like enzymes 
have been reported around the world 160.
Acinetobacter is a notorious pathogen of hot and humid climates, where it is a major cause of 
infections, particularly in intensive care units (ICUs) and within debilitated patients 156. Töölö 
hospital, which takes care of patients having suff ered an accident, burn unit patients and plastic 
surgery patients from the district of Helsinki and Uusimaa and partially from other parts 
of Finland, had a more serious problem with this bacterium in 2005. Th e tsunami disaster in 
Southeast Asia brought severe infections caused by multiple-resistant  A. baumannii to this 
hospital 162, 163. However, in the HUSLAB material from the district of Helsinki and Uusimaa the 
prevalence of multidrug resistant Acinetobacter spp. is nowadays very low (Figure 3) 148.  
Figure 3. Th e prevalence of multidrug resistant Acinetobacter spp. MDR isolates in HUSLAB between 
2001 and 2014. (Th e fi rst isolate only, screening excluded) MDR defi nition used in 2001-2010: 
nonsusceptibility to meropenem, tobramycin and piperacillin-tazobactam. From 2011 onwards: 
nonsusceptibility to meropenem and nonsusceptibility to at least two of the following: ceft azidime, 
fl uoroquinolone, aminoglycoside, ampicillin / sulbactam.
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1.6  Clostridium diﬃ  cile
Clostridium diffi  cile was fi rst identifi ed in 1935 as a component of the normal intestinal fl ora. Its 
ability to cause diarrhea and colitis was found in 1978 164. Both toxin-producing, toxigenic, and 
non-toxigenic strains exist naturally, and both can colonize their hosts, humans and mammals 
(such as horses, dogs and pigs), but only the toxigenic strains are associated with disease 165. 
Toxigenic strains have become a leading cause of hospital-acquired infections and are the major 
cause of antibiotic-associated diarrhoea, responsible for 15-25 % of all cases 166. Epidemiological 
reports from the United States have implied that C. diffi  cile has replaced MRSA as the most 
common cause of HAI 167. C. diffi  cile is usually acquired by the ingestion of spores via the fecal-
oral route. Spores are infective and highly resistant and facilitate C. diffi  cile persistence in aerobic 
environments. Transmission of C. diffi  cile in health care institutions is mediated primarily by 
spores 168. 
C. diffi  cile infection (CDI) can manifest itself as severe disease. Th e clinical features of C. diffi  cile 
can vary from asymptomatic carriage of infection to fulminant colitis, or pseudomembranous 
colitis, necessitating colectomy, and in some cases even leading to fatality. Th e major risk factors 
for CDI include high age, hospitalization, immuno-compromising conditions and exposure to 
certain antimicrobial agents, especially clindamycin, cephalosporins, and fl uoroquinolones. 
Furthermore, the combination of multiple antibiotics and longer duration of antibiotic use are 
associated with increased risk of developing CDI 169. Another clinically signifi cant property of 
CDI is its relatively high recurrence rate (5-47 % of cases) 170. Th e incidence and the mortality 
rate of CDI have considerably increased in both hospital and community settings due to the 
spread of hypervirulent strains and improper administration of antibiotics. One reason for that 
might be the aging of the population especially in the industrialized world, and it is well known 
that high age is an increased risk for CDI 171, 172. 
1.6.1  Toxins of C. diﬃ  cile
Toxigenic C. diffi  cile encodes one or two glucosyltranferase toxins, toxin A (TcdA) and toxin B 
(TcdB).  TcdA and TcdB belong to the same family of large clostridial glucosylating toxins and are 
considered to be the main virulence factors of C. diffi  cile. Th ese two related toxins are encoded 
by the 19,6 kb genomic island (fi ve-gene locus) known as the Pathogenicity Locus (PaLoc). Th ese 
toxins glucosylate and inactivate GTPases, including Rac, Rho and Cdc42 in host epithelial cells 
leading to signalling alterations and apoptosis 165. Th e Pathogenicity Locus includes the genes 
for three other proteins, TcdR, TcdE and TcdC, as well. C. diffi  cile toxin synthesis is negatively 
regulated by protein TcdC 173, 174. 
Some C. diffi  cile strains produce a third toxin, binary toxin CDT.  Binary toxin positive strains 
have become increasingly prevalent in the past ten years as a cause of CDI 175. Th is toxin is an 
ADP-ribosylating toxin that consists of two subunits: CDTa, which is the enzymatic component, 
and CDTb, the binding component. CDT is encoded by two genes cdtA and cdtB, which are 
transcriptionally linked and are located on the C. diffi  cile chromosome as a part of the CDT locus 
(CdtLoc) 176. 
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Toxigenic strains must produce at least one of the three known toxins, and fi ve toxin production 
patterns can be diff erentiated (Table 2).  Th e defi nition of a toxinotype in C. diffi  cile is based on 
the variability of the PaLoc region coding for two toxins, TcdA and TcdB 174.
Table 2. C. diffi  cile toxin production types 174, 175, 177. 
Toxin production type Toxinotype Ribotype
A+B+CDT+
Minor types
 XXIV 131
Major types
III
IV
V
VI
VII
IX
XIV
XV
XXII
XXIII
XXV
XXVIII
027, 034, 075, 080
023, 058, 059, 063
078, 126, 045, 066
045, 063, 066
063
019
111
122
ND
ND
027
126
A+B+CDT-
I
 II
 XII
 XIII
 XVIII
XIX-XXI
XXVI-XXVII
003, 012, 102
103
056
070
014
ND
ND
A-B+CDT+
X
XVI
XVII
Some V-like strains
XXX
XXXI
036
078
ND
ND
280, 281
237
A-B+CDT- VIII 017, 047
A-B-CDT+ XIa, XIbXI, Some strains without PaLoc
033
ND
A-B-CDT- Nontoxigenic strains
ND, not detected
1.6.2  DeleƟ ons in the tcdC gene of C. diﬃ  cile
Five lineages have been published that display diff erent types of deletions in the tcdC gene (the 
negative regulator gene of toxin production), such as 18 bp (associated or not associated with a 
deletion at position 117), 36 bp, 39 bp, and 54 bp 178. Th e notorious epidemic which was associated 
with a C. diffi  cile strain was characterized as toxinotype III (Table 2), North American PFGE type 
1 (NAP1), and PCR ribotype 027. Th e strain has a 18 bp deletion in the tcdC gene (at position 
330-347) 179, and produces the binary toxin (CDT) 180. Unlike the 18-bp deletion, a single-base-
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pair deletion at position 117 in the tcdC regulator gene represents a frameshift , leading to a stop 
codon and a truncated TcdC protein 181. Th e excessive toxin production is considered to be due to 
this defect in the TcdC protein. Th e normal inhibition of toxin production before the stationary 
phase is missing in these strains 180. However, the mechanisms that regulate the levels of toxin 
synthesis are only slowly being unravelled. Recently, the direct role for alterations in the tdcC as 
a predictor of hyperproduction of toxin A and B has been shown to be misleading 182. Toxins are 
positively regulated by tcdR and negatively regulated by tcdC, but tcdC may not be as important 
in toxin regulation as has previously been thought 183. Th e TcdE gene encodes a holin-like protein 
that may facilitate the release of toxins into the extracellular environment. Th e protein TcdE 
helps effi  cient secretion of toxins by a phage type system. Hence, under natural conditions  C. 
diffi  cile presumably expresses an amount of TcdE suffi  cient to form pores that allow release of 
toxin without causing cell lysis 184.
Th ere are also larger deletions than 18 bp in the tcdC-amplifi cation products. Th ese large 
deletions do not lead to truncations as such, but result in amino acid deletions in the putative 
protein products 185. Genotype tcdC-A contains a nonsense mutation at position 184 that is 
predicted to result in a severe truncation of the TcdC protein, and a 39 bp deletion at position 
341-379 in the tcdC gene. For example PCR ribotype 078, belonging to the toxinotype V (Table 
2), has both toxin genes, tcdA and tcdB, and binary toxin genes as well, and it has a 39 bp deletion 
in the tcdC gene. It has been reported that this strain can also cause severe CDI and increased 
mortality 186. Th ere is evidence for clonality of ribotype 078 that is frequently isolated worldwide 
from human infections and from animals used for food 187. A nonsense mutation at position 184 
and a 54 bp deletion at position 313-366 in the tcdC gene is another known large deletion 178, 188. 
In this study this deletion is assigned to genotype tcd-A variant (tcd-Avar) and these strains belong 
to the toxinotype IV and ribotype 023 groups (Table 2). TcdC gene sequences harboring a 36 bp 
deletion at position 301-336 have a mutation at position 191  178. Th e tcdC-variants with these 
larger deletions also contain stop codons comparable to the one detected in C. diffi  cile 027, and 
thus these variants may be potential hyperpoducers of toxins A and B 179.
1.6.3  C. diﬃ  cile carriage and prevalence
C. diffi  cile spores germinate in the gut to produce vegetative cells that express the toxins. While 
the toxins are responsible for the observed pathogenicity, the colonization of host mucosal 
surfaces is an essential fi rst step for CDI establishment. Asymptomatic carriage of C. diffi  cile 
aff ects 10-52 % of the defi ned populations 189. More specifi cally it has been estimated that 3-15 
% of healthy adults carry C. diffi  cile 190, and for infants the estimate is as high as 60-70 % 191. 
Aft er the recognition of a hypervirulent Clostridium diffi  cile (ribotype 027) in 2005 in Europe, 
the ESCMID Study Group on Clostridium diffi  cile (ESGCD) contacted the European Centre of 
Disease Prevention and Control (ECDC) and conducted several actions. Th e fi rst pan-European 
surveillance study, the “European Clostridium Infection Survey (ECDIS)”, was performed 
in 2008-2009. Th e incidence of C. diffi  cile varied between European hospitals, and detailed 
information was obtained from the ECDIS study group for 509 patients in 34 diff erent European 
countries. In this surveillance 65 diff erent PCR ribotypes were identifi ed, of which 014/020, 001 
and 078 were the most prevalent. Th e prevalence of PCR ribotype 027 was 5 % (Figure 4) 192.
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Figure 4. Geographical distribution of Clostridium diffi  cile PCR ribotypes in European countries in 
2008 with more than fi ve typeable isolates 192, copyright 2015.
In 2008 the most prevalent PCR ribotypes in Finland were 014 and 002, but the proportion of the 
hypervirulent strain PCR ribotype 027 was signifi cant as well 192. Th e fi rst case of fatal C. diffi  cile 
ribotype 027-associated disease was detected in October 2007 193. In 2014 5159 toxin producing 
C. diffi  cile cases were found in Finland and more than 20 % (1149 isolates) of them were found in 
the district of Helsinki and Uusimaa 77. 
1.6.4  IdenƟ fi caƟ on of C. diﬃ  cile
Th e diagnostic tests for C. diffi  cile can be divided into tests for C. diffi  cile products (glutamate 
dehydrogenase (GDH), aromatic fatty acids, toxins A and/or B), culture methods for the detection 
of toxin-producing C. diffi  cile (toxigenic culture, TC), and tests for C. diffi  cile genes (PCRs for 16S 
RNA, toxin genes, genes for GDH) 194. Toxigenic culture consists of culture on selective media 
followed by toxin detection. Th e selective and diff erential agar, such as cycloserine-cefoxitin-
fructose agar (CCFA), is the fi rst choice of isolation media for the identifi cation of C. diffi  cile 
from fecal samples. C. diffi  cile toxins can be detected by several methods: e.g. by cell culture 
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cytotoxicity assay (CCA), cell culture neutralization assays (CCNA), immunoassays, like enzyme 
immune assay (EIA) and immunochromatography, and PCR 194, 195. GDH is the common antigen 
of C. diffi  cile and it has proved to be commonly produced and conserved by both toxigenic and 
nontoxigenic isolates 196. EIA tests available include detection of GDH and toxin A only, or both 
toxins A and B. A test including both an EIA detecting toxin A and EIA detecting GDH is also 
available 194.
Strain typing can help with the infection control procedures by tracking the source and spread 
of C. diffi  cile infections. Several molecular typing methods, such as PCR ribotyping, pulsed-fi eld 
gel electrophoresis (PFGE), and multilocus variable-number of tandem repeat analysis (MLVA) 
are used as tools with C. diffi  cile 197. PCR ribotyping is the gold standard in typing C. diffi  cile in 
Europe and PFGE in the US.
1.7  Verifi caƟ on and typing of bacteria causing outbreaks 
1.7.1  Molecular methods for detecƟ ng bacteria causing outbreaks based 
on in-house PCRs 
PCR permits the synthesis of large quantities of a target nucleic acid sequence. PCR methods 
have been used routinely by reference laboratories as the standard for detecting and verifying 
microbes causing HAIs. Th e single PCR is the ancestor for the molecular methods used in 
diagnostic and epidemiological studies for the detection of antibiotic resistance or virulence 
genes 198. Multiple sets of primers can be induced in a single reaction tube (multiplex PCR). Th is 
increases the effi  ciency and reduces reagent costs. In the development of a multiplex PCR, the 
key strategy is the design of the primers; all of the primers should have very close annealing 
temperature optima. One must be sure that all primers in the reaction tube are mutually 
compatible, the formation of primer-dimers and other non-specifi c products should be avoided 
or minimized. Diff erent sizes for the intended amplicons allow the direct diff erentiation e.g. 
when PCR products are run in the agarose gel electrophoresis 199.
Th e real-time PCR consists of an amplifi cation reaction coupled with simultaneous detection 
of the exponentially amplifi ed target and visualization of the reaction phases. Th e number of 
cycles necessary to reach the exponential phase oft en depends on the initial quantity of target 
present in the reaction, allowing the quantifi cation of the DNA. Th e visualization is based on 
the fl uorescence emission occurring during the amplifi cation. Th e fl uorescence emission can 
be obtained using a  generic dye (e.g SYBR green), which fl uoresces when introduced in the 
double-strand DNA or using specifi c probes, such as hydrolysis probes (e.g. TaqMan®) harboring 
a fl uorophore at the 5´ end and a quencher (preventing fl uorescence emission) at the 3´ end. 
Hybridization/FRET probes harbor two diff erent fl uorescent labels. Th e molecular beacons 
consisting of the probe fl anked by two complementary sequences carrying a fl uorophore and 
a quencher at their endings, can be used as well 200. Th e analysis of melting temperature (Tm) 
curves allows a specifi c and easy discrimination of amplifi ed products obtained in a multiplex 
real-time PCR. Tm analyses provide discrimination between genes and allow the detection of 
gene variants 198.
Multiple free soft ware programs and websites are available to design primers and probes for 
PCR. Th ese tools oft en take into consideration the default requirements for primers and probes, 
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although new research advances in primer and probe design should be progressively added to 
diff erent algorithm programs. Aft er a proper design, a precise validation of the primers and 
probes is necessary 201.
Multiplex PCR methods, conventional and real-time, have been used to detect virulence 
factors and resistance genes from a variety of bacterial isolates and clinical specimens. Real-
time PCR avoids the time-consuming steps (e.g., electrophoresis analysis) and in many cases 
does not require DNA sequencing of the obtained products 198. Nowadays, there are many 
commercially available real-time PCR systems which are valuable for surveillance studies and 
rapid identifi cation of carriers 202-205.
1.7.2  Bacterial typing methods
Th e main role of microbial typing is to assess the relationships between microbial isolates. Typing 
enables to determine the source and routes of infections, confi rm or rule out outbreaks, trace 
cross-transmission of HAI, recognize virulent strains, and evaluate the eff ectiveness of control 
measures. Outbreaks of infectious diseases oft en result from exposure to a common source of the 
etiologic agent. Clonally related organisms are members of the same species that share virulence 
factors, biochemical traits, and genomic characteristics. However, there is suffi  cient diversity at 
the species level for organisms isolated from diff erent sources at diff erent times and in diff erent 
geographical regions to be diff erentiated or classifi ed into subtypes or strains 206.
Typing of bacteria can be useful at diff erent levels, such as locally (hospitals), regionally and 
nationally (in reference laboratories or research centers) and globally (through dedicated 
networks). Th e choice of typing methods depends on the level at which it is meaningful to 
perform typing. Th e process of subtyping is epidemiologically important for recognizing 
outbreaks of infection, detecting the cross-transmission of nosocomial pathogens, determining 
the source of infection, recognizing particularly virulent strains, and monitoring vaccination 
programs 207, 208.
Any subtyping method must have high diff erentiation power and be reproducible. It must be 
able to clearly diff erentiate unrelated strains, such as those that are geographically distinct from 
the source organism, and at the same time to demonstrate the relationship of all organisms 
isolated from individuals infected through the same source. Molecular methods diff er widely in 
their ability to diff erentiate strains. Reproducibility refers to the ability of a technique to yield the 
same result when a particular strain is repeatedly tested. Reproducibility is especially important 
for the construction of reliable databases containing all known strains within a species to which 
unknown organisms can be compared for classifi cation. Variable expression of phenotypic 
characteristics, such as sporadic expression of virulence genes or antigens, can contribute to 
problems with reproducibility 207, 209.
Typing methods can be classifi ed into phenotyping and genotyping methods. Phenotyping 
techniques detect the characteristics expressed by bacteria, while genotyping methods assess 
the variation in the chromosomal or extrachromosomal nucleic acid composition of bacterial 
isolates. Th e shortcomings of phenotypically based typing methods, such as antimicrobial 
susceptibility testing, serotyping and phage typing, multi locus enzyme electrophoresis (MLEE), 
or mass spectrometry have led to the development of typing methods based on the microbial 
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genotype or DNA sequence. Genotyping minimizes problems with typeability and reproducibility 
and, in some cases, enables the establishment of large databases of characterized organisms. 
Bacterial typing contributes to increase the eff ectiveness of surveillance systems and provides 
signifi cant clues to public health control strategies. Typing defi nes the extent of epidemic spread 
of bacterial clones and the number of clones involved in transmission and infection, monitoring 
the reservoirs of epidemic clones. Some molecular typing methods have been applied to study 
bacterial populations, evolution and the phylogenetic relationships between species 208, 209.
Th e molecular typing methods most commonly used are the DNA-based methods. Genotypic 
typing methods assess variation in the genomes of bacterial isolates with respect to composition, 
overall structure, or precise nucleotide sequence. Diff erent genotyping methods can be classifi ed 
into three main categories: hybridization-mediated, fragment-based (fi ngerprint methods) 
and sequence based methods 208.  Several methods have been introduced and developed for 
the investigation of the molecular epidemiology of microbial pathogens, such as restriction 
endonuclease analysis of genomic and plasmid DNA, southern hybridization analysis with the 
use of specifi c DNA probes, plasmid profi ling, chromosomal DNA-profi ling using either pulse-
fi eld gel electrophoresis or PCR-based methods. Each method has advantages and limitations. 
Several criteria should be considered when evaluating, validating and comparing typing 
methods 210. For performance, the following criteria should be taken into account: stability, 
typeability, reproducibility, discrimination power, Wallace coeffi  cient (a value indicating the 
probability that two strains classifi ed as the same type by one method are also classifi ed as the 
same by another method 211), concordance and test population. Other criteria include fl exibility, 
rapidity, accessibility, ease of use, cost, computerized analysis and data storage (Table 3) 208, 209, 212, 
213.
Table 3.  Characteristics of some main molecular typing systems. Adapted and modifi ed from Ranjbar 
et al., 2014 209.
Feature Pasmid 
analysis
 Ribotyping PFGE  Rep-PCR MLST 
Typeability  Many All All All All
Repeatability Moderate Excellent Excellent Good to 
excellent
Excellent
Reproducibility Moderate Excellent Excellent Good to 
excellent 
Excellent
Discriminatory 
power
Poor Moderate to 
excellent
Excellent Moderate to 
excellent
Good to 
excellent 
Stability   Moderate Good Good  Good  Good
Ease of interpretation 
of data generated
Moderate Moderate to 
good
 Moderate Moderate to 
good
Good 
Ease of use Moderate Poor to 
moderate
Poor Good Moderate
High throughput No No No Yes Yes
Cost Low High Moderate Low to 
moderate
Moderate
Time required (days) 1 1 to 3-5 3 1 >3
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Whole genome sequencing (WGS) is becoming increasingly competitive with any diagnostic 
technology, including traditional methods of culturing bacteria, and in a few years WGS could 
become the sole diagnostic and molecular epidemiological tool, involving identifi cation, genetic 
characterization and drug susceptibility testing 209.
1.7.2.1  Sequence based typing
Amplifi cation-based typing methods are also identifi ed as PCR-based methods. Th e PCR 
method, which is widely known as the most frequently applied nucleic acid amplifi cation 
and detection method, has had a substantial impact on the diagnosis and epidemiological 
investigation of infectious diseases. Specifi c microbial DNA sequencing has made it a powerful 
molecular tool. DNA sequencing-based genotyping of bacteria has signifi cantly contributed to 
many aspects of genotyping by identifying single nucleotide polymorphisms (SNPs), sequence 
deletions or insertions (including sequence duplications, such as VNTRs), and genes under 
positive selection 209, 214. For the past 30 years, the Sanger method has been the dominant approach 
and gold standard for DNA sequencing 215. It involves creating diff erent sizes of fl uorescently 
end-labelled PCR products in the same reaction tube. DNA fragments of varying lengths are 
synthesized by incorporating both nucleotides and dideoxy terminators, which are separated by 
agarose gel electrophoresis. Pyrosequencing is designated as a sequence-by-synthesis technique 
because DNA synthesis is monitored in real time. It is rapid and useful for genotyping (e.g for 
typing beta-lactamase genes 216) and organism identifi cation. Pyrosequencing relies on the 
detection of pyrophosphate release on nucleotide incorporation, rather than chain termination 
with dideoxynucleotides 217. Th e technique was fi rst demonstrated in 1987 by Pål Nyrén who 
showed that DNA polymerization can be monitored by measuring pyrophosphate production, 
which can be detected by light 218. 
In 1995, the fi rst whole bacterial genome was sequenced using conventional Sanger sequencing 219, 
and a decade later the advent of the fi rst high-throughput or next-generation sequencing (NGS) 
technologies became available. Th ese techniques deliver bacterial genome sequences in hours 
or days rather than in months or years, like before. Th e sequence data is also thousands of times 
cheaper than with Sanger sequencing. Nowadays there are many diff erent bench-top instruments 
(e.g. 454 GS Junior, Roche, Ion Proton, Life technologies, MiSeq, Illumina) that use diff erent 
kinds of sequencing technologies to produce sequence data. Th ey all are capable of sequencing a 
whole bacterial genome in one day 220.
Sequence data for specifi c loci (genes for virulence, drug resistance, etc.) from diff erent 
strains of the same species have revealed variability in specifi c genes, such as single nucleotide 
polymorphisms and areas with repetitive sequence that demonstrate a potential for 
epidemiological application. Th e single locus sequence typing (SLST) is a term for a variety of 
typing methods in which the sequencing of a single genetic locus provides a useful typing result. 
Th e target locus for SLST must be highly variable to be able to provide suffi  cient discriminatory 
power 208. For example, DNA sequencing of the polymorphic X region or the short sequence 
repeat (SSR) region 221 of protein A gene (spa) is the most popular technique for the typing of 
MRSA 222, 223. Th e polymorphic X region consists of 24 bp repeats and is located immediately 
upstream of the region encoding the C-terminal cell wall attachment sequence. Th e existence 
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of well-conserved regions in the spa gene allows the use of primers for PCR amplifi cation and 
direct sequence typing 224.
Multilocus sequence typing (MLST) compares the nucleotide sequences of internal 400- to 500 
bp regions of a series of housekeeping genes, which are present in all isolates of a particular 
species. MLST assesses DNA sequence variation among the alleles (usually fi ve to ten) of 
housekeeping genes 208.
Single nucleotide polymorphism (SNP) genotyping involves the determination of the nucleotide 
base that is present in a given isolate at defi ned nucleotide positions known to be variable within 
the population. SNP genotyping methods are primarily applied to defi ne the relationships among 
isolates of homogenous pathogens 208.
1.7.2.2  PCR ribotyping 
Ribotyping is a classic variant of a southern hybridization mediated assay that estimates the 
number of ribosomal gene loci and their position in the chromosome. It is reproducible, but 
usually has lower discriminatory power than PFGE, for example 212. Each ribosomal operon 
typically consists of three genes encoding the structural rRNA molecules, 16S, 23S, and 5S. Th e 
copy number, overall ribosomal operon sizes, nucleotide sequences, and secondary structures 
of the three rRNA genes are highly conserved within bacterial species. Th e 16S rRNA gene is 
the most conserved of the three rRNA genes, and 16S rRNA sequencing has been established 
as the gold standard for the identifi cation and taxonomic classifi cation of bacterial species. 
Knowledge of intraspecies conservation of the 16S rRNA gene and basic 16S-23S-5S ribosomal 
operon structure led to the fi rst insights into its usefulness in developing ribotyping for bacterial 
classifi cation 225, 226. PCR ribotyping was developed in 1990 for clinical microbiology laboratory 
purposes to discriminate pathogenic microorganisms without using probes, rendering the 
analysis more widely applicable. Th e method uses primers complementary to the 3´end of the 
16S rRNA gene and the 5´end of the 23 rRNA gene. PCR ribotyping reveals length heterogeneity 
of the PCR amplifi ed internal spacer regions located between the 16S and 23S genes 226. One 
species for which this method is widely used is C. diffi  cile, having a total of 11 ribosomal operons. 
Variation in the spacer region occurs not only between diff erent strains, but also between 
diff erent copies of the operon on the same chromosome 227.
1.7.2.3  Chromosomal DNA-profi ling based typing
Fragment-based methods include plasmid typing, restriction analysis, such as restriction 
endonuclease analysis (REA), pulsed fi eld gel electrophoresis (PFGE) and PCR fi ngerprinting 
methods, such as PCR restriction fragment length polymorphism (PCR-RFLP), amplifi ed 
fragment length polymorphism (AFLP), multilocus variable number tandem repeat analysis 
(MLVA) and repetitive PCR (rep-PCR) 208, 228.
1.7.2.4  PFGE
Restriction endonuclease analysis (REA) was the fi rst widely used method among restriction 
fragment length polymorphism (RFLP). In this method the chromosome was digested by 
frequently cutting restriction enzymes into several hundred small fragments, which were separated 
by horizontal gel electrophoresis into complex patterns. Th e pulsed-fi eld gel electrophoresis 
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(PFGE) technique made it possible to separate large DNA fragments in agarose gels by periodic 
alternation of the angle of the electric fi eld´s direction 214, 229. Th e bacterial chromosome is 
digested by spesifi c cutting enzymes which recognize specifi c DNA sequences of 6-8 bases, 
yielding a low to moderate number of fragments. Th is approach can resolve DNA fragments 
up to 800 kb in size. Point mutations, deletions, insertions and loss or acquisition of plasmids 
might account for minor diff erences in profi les within subtype or among epidemiologically 
related strains. Th ese changes usually result in two to three fragment diff erences in PFGE 
banding patterns. Th e generally accepted interpretation rule is that one isolate is closely related 
to another when the diff erence is around two to three fragments, possibly related when it is four 
to six, and unrelated when the diff erence is seven or more fragments 230. A visual comparison 
of profi les with usually only 10 to 20 bands is relatively easy, and computer-based analysis with 
the possibility of creating database libraries is available 231. PFGE has been the gold standard 
for typing and successfully used in short-term and long-term epidemiological investigations for 
many bacterial pathogens (e.g. C. diffi  cile, S. aureus) due to its high discriminatory power and 
reproducibility 210, 214, 223. Modifi ed PFGE protocols for subtyping previously non-PFGE typeable 
isolates have been developed e.g for C. diffi  cile 232. However, there are some shortcomings: PFGE 
is technically demanding, slow, and expressing low throughput, also the interpretation of band 
profi les is subjective and interlaboratory comparison of strain profi les is diffi  cult 214, 223.
1.7.2.5  Plasmid typing
Th e study of plasmids is important in medical microbiology because plasmids can encode genes 
for antibiotic resistance or virulence factors. As many species of bacteria contain plasmids, 
plasmid profi le typing has been used to investigate outbreaks of many bacterial diseases and 
to trace the inter- and intra-species spread of antibiotic resistance. Plasmid typing assesses the 
molecular size, numbers and restriction endonuclease digestion profi les of these bacterial extra 
chromosomal genetic elements, aft er agarose gel electrophoresis. Th is method has been used for 
the typing of many bacterial species, but typeability and discrimination are variable, depending 
on the bacterial species 233.
1.7.2.6  Repe? ? ve PCR (Rep-PCR) and DiversiLab 
A series of naturally occurring repetitive DNA sequences are dispersed in multiple copies 
throughout bacterial genomes. Th e PCR fi ngerprinting technique consists of PCR amplifi cation 
of spacer fragments lying between repeat motifs of the genome using consensus primers 
designed to be directed outwards from repetitive elements 208. Th ree families of repetitive 
sequences have frequently been used in REP-PCR assays: the 35-40 bp repetitive extragenic 
palindromic (REP) sequence, the 124-127 bp enterobacterial repetitive intergenic consensus 
(ERIC) sequence, and the 154 bp BOX element sequence 214. REP elements are 38 bp sequences 
consisting of six degenerate positions and a 5 bp variable loop between each side of a conserved 
palindromic stem in the bacterial genome. Multiple functions have been proposed for these 
highly conserved, dispersed REP elements, including roles in transcription termination, mRNA 
stability and chromosomal domain organization 234. Detection of DNA fragments is obtained 
when amplicons are separated by agarose gel electrophoresis of capillary electrophoresis to 
generate migration patterns that are compared to one another to determine genetic relatedness. 
Banding patterns diff er as a result of the number of repetitive elements and their relative position 
within the bacterial genome 209.  Because of the low cost of materials, rapidity, ease of use and 
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low labor intensity, rep-PCR may be a valuable tool for bacterial strain typing. On the other 
hand, reproducibility can be aff ected by variability in PCR reagents, thermal cycling and gel 
electrophoresis conditions.
Healy and coworkers developed a semi-automated rep-PCR in 2004 228, 235. Th is was 
commercialized and integrated to bioMérieux (DiversiLab, bioMérieux, Marcy l´Étoile, France) 
for application to clinical laboratories. Th e DiversiLab method uses primers targeting noncoding 
repetitive sequences interspersed throughout the bacterial genome 234, 236. Th e modifi cations for 
automation include changes in rep-PCR chemistry and thermal cycling parameters. Th e method 
uses microfl uidic chip-based DNA fragment separation (Agilent 2100 Bioanalyzer, Agilent 
Technologies, Inc. Paloalto, CA, USA) unlike the traditional gel electrophoresis. Th e system also 
provides data analysis soft ware to compare the banding patterns and to generate dendrograms 
and an online database for strain identifi cation and typing 228. Th e DiversiLab soft ware allows 
multiple report options to make interpretation easier. In order to compare the rep-PCR 
fi ngerprints, the electropherograms, or sample graphs are analyzed. For the calculation of 
percent similarities three options exist: Pearsson correlation (PC), the modifi ed Kullback-Leibler 
(KL) and extended Jackard (XJ) coeffi  cients to determine the distance matrices. All methods 
calculate similarity based on the relative intensities of the sample pair at each datapoint; however, 
they each place a diff erent emphasis on peak intensity and presence. Th e unweighted pair group 
method with an arithmetic mean (UPGMA) is used to create dendograms and scatter plots. 
More detailed clustering and outbreak analysis can be performed by using the pattern overlay 
analysis (DiversiLab analysis soft ware, version 3.4).
Th e method has been successfully used to distinguish several diff erent bacteria, fungi 
and archaea 237. At fi rst, the method was used to diff erentiate Aspergillus isolates in 
2004 235. In 2005 it was used for the typing of S. aureus 238 and MRSA 239, and for the 
identifi cation of dermatophytes 240. In 2006 the method was applied for the identifi cation 
of  Coccidioides  species,  Blastomyces dermatitidis and Histoplasma capsulatum 241, as well as 
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for typing vancomycin-resistant enterococci 242. For the identifi cation and diff erentiation of 
Candida spp. it was employed in 2007 243. Aft er 2008 DiversiLab has been used increasingly 
(Figure 5) and mostly for the typing of Gram-negative rods, such as Acinetobacter 155, 244-247, ESBL 
producers 248-253, carbapenemase producers 254-256, Serratia marcescens 257, Salmonella spp. 258-260, 
and Pseudomonas aeruginosa 261. Th e DiversiLab method has also proved to be suitable for typing 
C. diffi  cile isolates as demonstrated for the fi rst time in this study (Study IV), and subsequently 
also by other authors 262-265. Accordig to bioMérieux, there are currently approx. one hundred 
DiversiLab users in Europe. 
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Figure 5. Usage of the DiversiLab method according to the publications in PubMed.
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2.  THE AIMS OF THE STUDY
I Rapid identifi cation of hospital-acquired infections by establishing new molecular methods 
(multiplex PCRs)
MRSA-PCR: To assess a sensitive, reliable MRSA-PCR method suitable for daily use in 
a microbiological diagnostic laboratory enabling faster reporting of negative MRSA 
screening results. 
Carbapenemase gene-PCR: Real-time multiplex PCR for detecting and verifying 
carbapenemase genes.
C. diffi  cile-PCR: Conventional multiplex PCR for detecting and screening hypervirulent 
C. diffi  cile and other potentials toxin hyperproducer strains.
II Rapid outbreak analysis for hospital-acquired bacteria outside of the national reference 
laboratory
III Comparison of commercial repetitive PCR (DiversiLab) with other molecular typing methods 
Th e Aims of the Study
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3.  MATERIALS AND METHODS
3.1  Bacterial isolates 
Finland is divided into 20 hospital districts of which fi ve are university hospital districts, of these 
the Hospital District of Helsinki and Uusimaa (HUS) is the largest. HUSLAB, the laboratory in 
the Helsinki and Uusimaa region analyzes the microbiological samples from 24 municipalities 
and 21 hospitals throughout the province of Uusimaa (Figure 6). Th e Joint Authority is made 
up of fi ve hospital areas: the Helsinki University Central Hospital (HUCH), Hyvinkää, Lohja, 
Porvoo and Länsi-Uusimaa Hospital areas. Th is area is responsible for the secondary and tertiary 
care of approximately 1,5 million people and has approximately 2800 hospital beds. In 2013 HUS 
was treating more than 500 000 patients and carrying out 87 000 surgical operations per year 266. 
Figure 6. Th e province of Helsinki and Uusimaa, copyright 2015 267.
Th e bacterial isolates used in the diff erent studies are presented in Table 4. Two kinds of sets of 
bacterial isolates were used: consecutive screening samples (MRSA and C. diffi  cile), and clinical 
isolates collected retrospectively (MRSA, ESBL and A. baumannii).
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Table 4. Strain settings used in this study.
BACTERIUM NUMBER 
OF 
ISOLATES
DESCRIPTION OF 
ISOLATES 
REFERENCE COLLECTION 
YEAR
MRSA 1250
69
132
Clinacal screening samples 
Vaasa outbreak
HUS culture collection 
samples (“reference strains”)
V
III
III
Sep-Nov 2005
2003-2010
ESBL strains of 
Enterobacteriaceae: 
(E. coli, K. 
pneumoniae, K. 
oxytoca, E. cloacae)
39     
            
30
Isolates from 20 patients of 
the pediatric surgery ward
Clinical samples, negative 
controls
II 2004-2008
Acinetobacter 
baumannii
51
4
Clinical isolates with 
reduced susceptibility
Clinical samples, negative 
controls
I 1993-2008
Clostridium diffi  cile 730
205
Concecutive clinical 
screening samples
Two sets of concecutive 
clinical isolates from THL 
and HUSLAB
VI
IV
2007-2008
2007-2008
HUSLAB received a total of 68873 MRSA screening samples in 2005 from health care centers, 
nursing homes, secondary-care and tertiary-care hospitals, and 1250 of them were analyzed in 
the validation of multiplex PCR for excluding MRSA. Today we receive approximately 82000 
screening samples yearly. In the comparison of DiversiLab with other typing methods Vaasa 
outbreak isolates (n=69) and culture collection isolates (n=132) of HUSLAB were used.
In autumn 2007 an increasing number of ESBL-producing E. coli, K. pneumoniae, and 
surprisingly E. cloacae isolates were detected in one ward of our University Children’s Hospital. 
All identifi ed ESBL isolates (n=39) from this ward were studied using the DiversiLab system.
Carbapenemase PCR was validated from clinical samples using 710 isolates of A. baumannii, 
P. aeruginosa and Enterobacteriaceae with reduced susceptibility during 2008-2011. In the 
characterization of A. baumannii clones using the DiversiLab system 55 Acinetobacter isolates 
were analyzed.
In 2007 the fi rst hypervirulent C. diffi  cile isolate was identifi ed and an epidemic situation started 
in Finland. Th e multiplex PCR was applied on a total of 730 toxin positive C. diffi  cile isolates 
from consecutive clinical screening samples. In the comparison of DiversiLab with other typing 
methods two sets of consecutive isolates (n=205) from THL and HUSLAB were used.
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3.2  Classical methods
All bacterial isolates were cultured on a suitable agar (Table 5) and incubated in suitable 
conditions, respectively. Colonies expressing typical morphology and biochemistry were 
identifi ed as described in table 5. In addition, Gram-staining was used when necessary. Th e 
antimicrobial susceptibility of the MRSA isolates was tested according to the guidelines of the 
Clinical and Laboratory Standards Institute (CLSI) (Study I, II, III, V) 268.
Table 5. Classical methods used in this study.
Culture Source Identifi cation 
tests
Source
MRSA Chocolate agar BBL 211047 / BBL 
212257
Tube coagulase 
test
Labema OY, 
Kerava, Finland      
ORSAB agar 
(agar base, Oxacillin 
2 μg/ml, polymyxin 
B 50 IU/ml)
Oxoid™ CN 1008 Staphaurex 
latex test
Remel Europe, 
Dartford, UK
MRSA ID bioMérieux, Bortel, 
Netherlands
Accu probe Gen Probe, San 
Diego, USA
Selective MRSA 
enrichment broth
Study V API staph/
Staph ID 32
bioMérieux,Marcy 
l’Etoile, France
ESBL CLED (cysteine 
lactose electrolyte 
defi cient) agar / 
CLED + cefuroxime
BBL, Cat. No. 212218, 
Becton Dickinson, NJ, 
USA
Cefuroxime 16mg/l, 
Orion Pharma, Espoo, 
Finland
API20E bioMérieux,Marcy 
l’Etoile, France
chromID® ESBL bioMérieux,Marcy 
l’Etoile, France
A. baumannii CLED agar BBL, Cat. No. 212218, 
Becton Dickinson, NJ, 
USA
VITEK 2 bioMérieux,Marcy 
l’Etoile, France
16S rRNA 
sequencing
in-house
C. diffi  cile CCFA agar 269 Premier Toxins 
A&B-test kit
Meridian  Biosence 
Inc., Cincinnati, 
OH, USA
3.3  Molecular methods
DNA was extracted from clinical samples (MRSA) or colonies on bacterial plates by methods 
described in table 6 following the manufacturer´s instructions. Both conventional and real-time 
PCR was used.
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Table 6. Nucleic acid methods used in this study.
DNA Extraction Source PCR Reference
MRSA Magna Pure LC DNA 
isolation kit III
Roche, Basel, 
Switzerland
Real-time duplex 
(mecA-nuc) MRSA-
PCR
Study V
Easymag bioMérieux,Marcy 
l’Etoile, France
UltraClean Microbial 
DNA isolation kit
MoBio Laboratories, 
Solana Beach, CA, 
USA
ESBL Boiling a bacterial 
suspension for 10 min 
at 95°C
270 Conventional PCR 
for ESBL genes 
(THL)
270
UltraClean Microbial 
DNA isolation kit
MoBio Laboratories, 
Solana Beach, CA, 
USA
A. baumannii Boiling in TE (10 mM 
Tris-HCl, 1 mM EDTA, 
pH 8,0) buff er
Real-time multiplex 
carbapenemase gene-
PCR 
(17 carbapenemase 
genes)
Study I
UltraClean Microbial 
DNA isolation kit
MoBio Laboratories, 
Solana Beach, CA, 
USA
C. diffi  cile Boiling in TE (10 mM 
Tris-HCl, 1 mM EDTA, 
pH 8,0) buff er
Conventional 
multiplex C. diffi  cile-
PCR
Study VI
UltraClean Microbial 
DNA isolation kit
MoBio Laboratories, 
Solana Beach, CA, 
USA
3.3.1  Real-Ɵ me MRSA-PCR based on probes (Study V)
Th e primers and probes for MRSA-PCR were designed with Primer Express® soft ware (v2.0; 
Applied Biosystems, Foster City, CA, USA) and the specifi city was characterized by sequencing 
the amplifi cation products. Th e designed assay is based on 5’ nuclease chemistry utilizing two 
primers and a hydrolysis probe (Taqman®) and it employs exonuclease activity of Taq DNA 
polymerase. Th e PCR reaction mixture included QuantiTect Multiplex PCR master mix (cat 
No. 204543; Qiagen, Valencia, Spain), optimized primer-probe-mix, Urasil-DNA-glycosylase 
(UDG, 2U/ml; New England Biolabs, Ipswich MA, USA), and template DNA. Th e PCR run was 
performed using the Rotor-Gene 2000 Real-time amplifi cation system (Corbett Research, Sydney, 
Australia) or using Stratagene Mx3005P (Stratgene, La Jolla CA, USA), and the amplifi cation was 
performed as follows: 1 cycle at 50 °C for 2 min, 1 cycle at 95 °C for 10 min, followed by 40 cycles 
with a denaturation step at 95 °C for 15 sec, and annealing and an extension step at 60 °C for 1 
min.
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Table 7. Primers and probes designed for MRSA-PCR.
Gene Primer Sequence 5´- 3´ Probe Sequence 5´- 3´
nuc nuc-F GCTTAGCGTATAT
TTATGCTGATGGA
nuc 5´-FAM-AAATGGTAAACGAAGCTT-BHQ1-3´
nuc-R TTTAGCCAAGCCT
TGACGAACT
mecA 5´-VIC-CCCTCAAACAGGTGAATT-BHQ1-3´
mecA mecA-F GATTATGGCTCAG
GTACTGCTATCC
mecA-R ATGAAGGTGTGCT
TACAAGTGCTAA
3.3.2  Real-Ɵ me carbapenemase gene-PCR based on an intercalaƟ ng dye 
(Study I)
Th e design for carbapenemase gene-PCR was performed using AlleleID soft ware 271, taking into 
account all the globally known sub-variants in the National Center for Biotechnology Information 
(NCBI) data base. Th e assay was designed to utilize an intercalating dye (SYBR® Green) which 
is a non-sequence-specifi c fl uorescent dye that exhibits a large increase in fl uorescence emission 
when introduced into double stranded DNA. Th e assay was divided into two multiplex reactions 
consisting of nine and eight gene families, respectively (Table 8) and validated using 43 control 
strains confi rmed at the National Institute for Health and Welfare 145. In addition, synthetic gene 
constructs for SFC, CMY-1/10, SIM, SME, OXA-25 and OXA-58 genes were used. All gene 
products were confi rmed by sequencing with reference primers or the gene specifi c primer alone. 
Th e OXA-51 gene with or without ISAba1 was detected separately using primers: F_OXA51_
AATTTATTTAACGAAGCACACACTACGG and R_OXA51_001 (Table 9). Th e PCR reaction 
mixture included Maxima SYBR green qPCR master mix (2X) (Scientifi c Fermentas, Schwerte, 
Germany), optimized oligomix 1 or 2 (IDT, Integrated DNA Technologies, Inc), and template 
DNA. Th e PCR run was performed using Stratagene Mx3005P. Th e amplifi cation was performed 
as follows: 95 °C 10 min initial denaturation, 30 cycles 95 °C 20 sec denaturation, 58 °C 30 sec 
annealing and extension, fi nal extension at 58 °C 1 min and fi nal denaturation 95 °C 30 sec. Th e 
melting curve was determined between temperatures 58-95 °C.
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All positive isolates with an expected melting curve were confi rmed by further analysis using 
conventional PCR and by sequencing the carbapenemase gene (Table 9). Th e reaction included 
HotStar Taq polymerase (Qiagen, Helsinki, Finland), polymerase buff er 10 X, dNTP-mix (2,5 
mM), forward and reverse primers for genes predicted from the melting curve, and template 
DNA. Amplifi cation was performed as follows: initial denaturation 95°C 15 min, 35 cycles with 
denaturation 94°C 30 sec, variable annealing temperature 55/60/62°C 30 sec depending on the 
carbapenemase gene to be amplifi ed, extension 72°C 1 min, and fi nal extension 72°C 10 min, 
using the DNA Engine Tetrad 2 Peltier Th ermal Cycler (Bio-Rad, Hercules, CA, USA). 
Table 9. Primers used for sequencing carbapenemase genes.
Gene Primer Sequence (5’- 3’) Size (bp) T (m) Reference
IMP-1 F_IMP-1
R_IMP-1
TGAGCAAGTTATCTGTATTC
TTAGTTGCTTGGTTTTGATG
740 55 134
IMP-15 F_IMP-2
R_IMP-2
GGCAGTCGCCCTAAAACAAA
TAGTTACTTGGCTGTGATGG
737 55 134
IMI F_IMI
R_IMI
ATAGCCATCCTTGTTTAGCTC
TCTGCGATTACTTTATCCTC
818 55 134
KPC F_KPC
R_KPC
ATGTCACTGTATCGCCGTCT
TTTTCAGAGCCTTACTGCCC
893 55 134
GES F_GES
R_GES
GTTTTGCAATGTGCTCAACG
TGCCATAGCAATAGGCGTAG
371  60 134
VIM-1 F_VIM-1
R_VIM-1
TTATGGAGCAGCAACCGATGT
CAAAAGTCCCGCTCCAACGA
920  60 134
VIM-2 F_VIM-2
R_VIM-2
AAAGTTATGCCGCACTCACC
TGCAACTTCATGTTATGCCG
865  60 134
OXA-48 F_OXA-48
R_OXA-48
TTGGTGGCATCGATTATCGG
GAGCACTTCTTTTGTGATGGC
744 62 134
GIM F_GIM-1
R_GIM-1
AGAACCTTGACCGAACGCAG
ACTCATGACTCCTCACGAGG
748  60 134
SPM F_SPM-1
R_SPM-1
CCTACAATCTAACGGCGACC
TCGCCGTGTCCAGGTATAAC
650 55 134
SME F_SME
R_SME
AAGGCTCAGGTATGACATT
GGCATAATCATTCGCAGTA
410  60 Study I
SIM F_SIM-1
R_SIM-1
TACAAGGGATTCGGCATCG
TAATGGCCTGTTCCCATGTG
571  60 134
OXA-24 
family
F_OXA24
R_OXA24
GAATATGTCCCTGCATCAAC 
ACCAGTCAACCAACCTAC
477  60 Study I
OXA-23 
family
F_OXA23
R_OXA23
GTGTCATAGTATTCGTCGTTAG
TATCAACCTGCTGTCCAAT
592  60 Study I
ISaba1/ 
OXA-51
F_IS51
R_OXA51
GTCATAGTATTCGTCGTTAGA
GCACGAGCAAGATCATTACCATAGC
301 60 Study I
CMY-10 F_CMY
R_CMY
TAAGATACTTCGGATGAGGAG
GCATCTTCTCGGATGAATC
695  60 Study I
SFC F_SFC
R_SFC
CTCATTCTCCTGTGACTGA
TTGCTCCTCCTGTTGTATT
351  60 Study I
NDM F_NDM
R_NDM
GACAACGCATTGGCATAAG
AAAGGAAAACTTGATGGAATTG
447  60 Study I
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3.3.3  ConvenƟ onal C. diﬃ  cile-PCR (Study VI)
For the detection of toxin-producing C. diffi  cile a conventional multiplex PCR was designed. 
Th is PCR detects the genes tcdA, tcdB, cdtA, cdtB, tcdC and the size of the possible deletion in the 
tcdC gene (Table 10). Primers for amplifying the 139 bp fragment of the tcdC gene were designed 
using PRIMER EXPRESS-soft ware (version 1.5; Applied Biosystems, Foster City, CA, USA). 
Th e specifi city of amplifi cation products was characterized by sequencing. Th e PCR reaction 
included 0,2 mM dNTP-mix (Finnzymes, Espoo, Finland), 0,5 mM MgCl2 (Applied biosystems), 
1 U Phusion-polymerase (Finnzymes), 1 X enzyme buff er, optimized primer mix and template 
DNA. Th e PCR run was performed using the DNA Engine Tetrad 2 Peltier Th ermal Cycler (Bio-
Rad) and the amplifi cation was performed as follows: initial denaturation step at 98 °C , 36 cycles 
at 98 °C for 10 sec, 60 °C for 20 sec and 72 °C for 20 sec, followed by fi nal extension at 72 °C for 
10 min. Th e PCR products were run in 2,5 % Nusieve GTG agarose (Lonza, Basel, Switzerland) 
in TBE buff er, 120 V for 2,5 h.
Table 10. Primers used for the amplifi cation of C. diffi  cile toxin producing genes.
Gene Primer Sequence (5´-3´) Reference
cdtA cdtApos
cdtArev
TGAACCTGGAAAAGGTGATG
AGGATTATTTACTGGACCATTTG
272
cdtB cdtBpos
cdtBrev
CTTATTGCAAGTAAATACTGAGAGTACTATATC
ACCGGATCTCTTGCTTCAGTC
Modifi ed from 
Stubbs 272
tcdA TA1
TA2
ATGATAAGGCAACTTCAGTGG
TAAGTTCCTCCTGCTCCATCAA
273
tcdB1 TB1
TB2
GAGCTGCTTCAATTGGAGAGA
GTAACCTACTTTCATAACACCAG
273
tcdB2 NK104
NK105
GTGTAGCAATGAAAGTCCAAGTTTACGC
CACTTAGCTCTTTGATTGCTGCACCT
274
tcdC tcdC52/121-F
tcdC121-R
AAGCTATTGAAGCTGAAAATC
GCTAATTGGTCATAAGTAATACC
Study VI
3.3.4  DiversiLab (Study I, II, III and IV)
Th e automated repetitive extragenic palindromic sequence-based PCR (rep-PCR), DiversiLab, 
was validated in this study for analyzing outbreaks caused by hospital-acquired bacteria. Th e 
DiversiLab analysis was performed on all bacteria examined (Table 11). DNA was amplifi ed 
using the bacterium specifi c DiversiLab kits (Bacterial Barcodes, Athens, GA, USA), and DNA 
fi ngerprinting was performed following the manufacturer´s instructions. Th e PCR run was 
performed using the preheated DNA Engine Tetrad 2 Peltier Th ermal Cycler (Bio-Rad, Hercules, 
CA, USA). Th e rep-PCR products were detected and the amplicons were separated using the 
microfl uidics lab-on-chip technology (Agilent 2100 Bioanalyzer, Agilent Technologies, Inc. 
Paloalto, CA, USA), and analyzed using the Diversilab system. Further analyses were performed 
using the web-based DiversiLab soft ware (version 3.4) applying the band-based modifi ed 
Kullback-Leibler distance for the calculation of percent similarities. For MRSA, pattern overlay 
analysis was done, as well. Th is method was compared with other typing methods, such as 
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PFGE, PCR ribotyping and spa typing (SLST). Two diff erent gene sequencing based methods, 
the CTX-M gene sequencing in ESBL strains and the tcdC gene sequencing in C. diffi  cile strains, 
were also used.
Table 11. Typing methods used in this study.
Typing method Reference
MRSA DiversiLab (Study III)
PFGE (THL)
spa typing (THL)
bioMérieux,Marcy l’Etoile, France
275, 276
66
ESBL DiversiLab (Study II)
PFGE (THL)
CTX-M gene pyrosequencing (THL)
bioMérieux,Marcy l’Etoile, France
277
270
A. baumannii DiversiLab (Study I) bioMérieux,Marcy l’Etoile, France
C. diffi  cile DiversiLab (Study IV)
PCR ribotyping (THL)
PFGE (THL)
Conventional PCR and tcdC gene sequencing 
(Study VI)
bioMérieux,Marcy l’Etoile, France
227
232
273
All of the molecular methods used in this study are concluded in table 12.
Table 12. Conclusion of the molecular methods used in this study.
PCR METHODS
Conventional PCR Real-time PCR
 Detection of ESBL genes
 Verifi cation of positive carbapenemase 
genes
 Multiplex PCR for the detection of 
toxigenic C. diffi  cile
 Multiplex PCR for the detection of 
mecA and nuc genes of MRSA
 Multiplex PCR for the detection of 
carbapenemase genes
TYPING METHODS
Typing methods based on 
sequencing
Typing methods based on PCR Typing methods based on 
the analysis of chromosomal 
DNA
 spa typing (SLST)
 ESBL gene sequencing
 Carbapenemase gene 
sequencing
 TcdC gene sequencing
 PCR ribotyping  PFGE
 rep-PCR
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4.  RESULTS AND DISCUSSION
4.1  IdenƟ fi caƟ on of bacteria causing outbreaks by new 
mulƟ plex PCRs (Study I, V, VI)
In this study three diff erent in-house multiplex PCR methods were established for our clinical 
laboratory. Th e goal was to detect the possible HAI strains faster and more easily. In addition, 
a MRSA enrichment broth was developed, and this broth is still used in the routine diagnostics 
in our laboratory. Th e multiplex PCR methods were 1) detection of MRSA by duplex PCR 
detecting nuc and mecA genes, 2) detection of 17 diff erent carbapenemase gene groups of 
Enterobacteriaceae by real-time multiplex PCR, and 3) detection of toxigenic C. diffi  cile by 
multiplex conventional PCR, including detection of toxin hyperproducer strains. All of these 
three in-house methods are still in our daily routine use, as well. 
4.1.1  MRSA-PCR (Study V)
1250 clinical samples were isolated for the validation of duplex PCR detecting nuc and mecA 
genes. Among these isolates 31 (2.5%) MRSA strains from 21 patients were found. FIN-21 (spa 
type t041, MLST ST type 228) was the most common type (46%, 15 strains from 14 patients), 
and was one of the epidemic types in Finland at that time 275. Th e sensitivity of the test was 
93.5%, specifi city 88.6%, positive predictive value 17.3% and negative predictive value 99.8% 
as compared to culture (Study V). Using the MRSA-PCR combined with enrichment broth, 
89% of the truly negative samples can be reported correctly. Th is was in agreement with other 
methods using a S. aureus specifi c marker combined to mecA and a cefoxitin-based enrichment 
medium 81, 278, 279. Cefoxitin enhances the growth of heteroresistant MRSA-strains more effi  ciently 
and the use of a cefoxitin-based enrichment medium increased the MRSA detection rate as 
compared to plate culture only. Th is increased sensitivity brought about by broth enrichment is 
commonly acknowledged 78. 
A clear correlation between the Ct values of nuc and mecA was seen in the samples containing 
MRSA, whereas in the samples negative for MRSA such correlation did not exist when the cut-
off  value was set to 30 cycles. A heavy load of methicillin-sensitive S. aureus and methicillin-
resistant coagulase negative Staphylococcae (nuc negative) is oft en found in MRSA screening 
samples potentially increasing the number of false positives. Th erefore nuc (S. aureus specifi c 
gene) was combined with the methicillin-resistance gene, mecA, for the screening method. Th is 
MRSA-PCR screening method enables us to provide clinicians rapid reliable negative MRSA 
results. Broth enrichment combined to the duplex PCR-method allows the reporting of negative 
samples on the following day aft er receiving the sample. Using the culture technique a negative 
report can be given on day three, thus the PCR method speeds up the process by two days which 
may be considered benefi cial. Th e sooner the result of the MRSA screening test is available in the 
clinic, the sooner the control measures, namely isolation, cohorting and surveillance of cultures 
of contacts, can be undertaken 280.
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Th e designed MRSA-PCR is a high throughput method and applicable to all machinery 
compatible with a 5’ nuclease chemistry utilizing a hydrolysis probe. It uses standard probes and 
laboratory personnel time is taken up only moderately. Th e costs are relatively low and it has a 
very high throughput. Th e method also optimizes the capacity of a laboratory having opening 
hours from 8 a.m. to 8 p.m. It is suitable for the work fl ow to combine MRSA culture and MRSA-
PCR for verifying the positive result if needed. Options for these kinds of solutions are needed 
when cost-eff ectiveness is demanded of clinical laboratories. Many commercial solutions for 
screening have recently come up 85, 281, 282. Th us, the molecular diagnostics of MRSA remains 
challenging even in this era of several commercial, validated MRSA-PCR-tests. At the time of the 
study one option, the BD GeneOhm™ MRSA assay, was studied in our laboratory. Th is assay was 
not able to reliably detect strains belonging to PFGE types FIN-7, FIN-31, FIN-35. Th e strains 
harbored SCCmec types IV, V, VI, or a novel type. In addition, single false-negative or weak-
positive reactions were seen in a few other PFGE types. It was concluded that we could not rely 
on the BD GeneOhm™ MRSA assay in our epidemiologic situation and it was not tested with any 
actual patient swabs 205. To conclude, the combining of the enrichment broth to the MRSA-PCR 
suggested by us was considered to be more reliable and applicable.
Th is reasonably rapid, robust, enrichment broth based on the nuc-mecA-PCR-application is 
suitable for diagnostic microbiological laboratories for the screening of MRSA. Th e method is not 
able to detect the mecC gene. For cases where the mecA result is negative and the susceptibility 
to oxacillin or cefoxitin is reduced our laboratory has set up a new real-time PCR for detecting 
the mecC gene (unpublished). Up to now only one mecC positive strain has been found in the 
HUSLAB material.
4.1.2  Carbapenemase gene-PCR (Study I)
Th e carbapenemase detection assay was developed to detect carbapenemase producing 
Enterobacteriaceae, but was found to be a useful tool for Pseudomonas aeruginosa and A. 
baumannii as well. Earlier, a multiplex PCR for carbapenemase genes had been developed 
by Poirel et al., but this multiplex did not include OXA-23, OXA-58 and OXA-24/40, the 
genes commonly found in A. baumannii 283. Th e assay developed here detects 17 diff erent 
carbapenemase genes (Study I), and the multiplex PCR proved to be sensitive and highly specifi c. 
Th e assay was tested using 710 isolates of A. baumannii, P. aeruginosa and Enterobacteriaceae 
with reduced carbapenem susceptibility. CPE strains are increasingly found in Finland, but still 
at a very low prevalence. In the HUSLAB material from 2008-2014 a total of 53 enterobacterial 
strains (including IMI, KPC, OXA-48, VIM, NDM, GES, OXA-181, SME and NCM-A enzymes) 
were found, the most prevalent genes being KPC (38 %) and NDM (30 %) (Figure 7) 148. Th e 
spread of KPC, NDM and OXA-48 is already known worldwide 35, 284. 
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Figure 7. Carbapenemase producing Enterobacteriaceae in HUSLAB between 2008 and 2014.
Th is carbapenemase gene-PCR was used to characterize the carbapenemase genes of A. 
baumannii isolates with reduced susceptibity to carbapenem. In A. baumannii, only oxacillinase 
genes were found, of which the most prevalent were OXA-23-like gene (33/55, 60 %) and the 
the OXA-58 gene (8/55, 15 %). Only one OXA-24/40-like gene was found. Th e emergence and 
spread of several outbreaks of sporadic A. baumannii strains producing an OXA-23-like enzyme 
have been reported around the world 285. Th e ISAba1-OXA-51 junction PCR was negative in 
all strains. ISAba1 is providing a strong promoter activity for the blaOXA-51-like gene, and 
probably for the OXA-23-like gene 286. Th e ISAba1 associated OXA-23 gene in A. baumannii was 
found to increase imipenem resistance and dissemination in an intensive care unit in China 287.
One major problem related to molecular detection is the appearance of new genomic variants. 
Th is problem is aff ecting the detection of many antibiotic resistance genes. For example six 
OXA-48 variants (OXA-48, OXA-162, OXA-163, OXA-181, OXA-204 and OXA-232) have been 
identifi ed, with OXA-48 being the most widespread. Th e variable regions of the OXA-181 enzyme 
diff er from OXA-48 by only four amino acid substitutions and have been found to be associated 
with other carbapenemase genes 142. Up to now the GES family includes 27 variants, KPC includes 
24 variants and NDM includes 16 variants 107. Th e phenotypes of the carbapenemase producing 
bacteria are highly variable and many overlapping resistance mechanisms can appear. Finding 
a simple screening method for detecting them all is very challenging. At the time of the study 
no simple method suitable for routine clinical screening was available. Primers for this assay 
were designed for conserved gene regions to achieve optimal amplifi cation of all the current and 
hopefully forthcoming sub-variants. Th is multiplex assay is very comprehensive compared to 
the commercial multiplex PCRs, such as Check-Direct CPE, easyplex® SuperBug complete A or 
Xpert® Carba-R,  which will usually detect only fi ve main carbapenemase families, KPC, OXA-
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48, NDM, VIM and IMP (usually including only IMP-1 variant) associated with outbreaks. Th ese 
tests can be used to detect genes directly from a clinical screening sample or they may be used to 
search for the genes from isolates with reduced susceptibility 288. Th e multiplex PCR developed 
in this study has also been tested directly from clinical faecal samples (spiked samples) using a 
reduced gene set and the results were promising (data not shown).
Today there are many commercial rapid screening tests to identify carbapenemase producers in 
Enterobacteriaceae 150, 289. Th e carba NP test is based on a technique that identifi es the hydrolysis 
of the betalactam ring of carbapenem in carbapenemase-producing Enterobacteriaceae (290). 
Carba NP and Rapid CARB screen Kit (Rosco Diagnostica A/S, Taastrup, Denmark) both 
base on in vitro hydrolysis of imipenem. Th e New NucliSENS EasyQ KPC (BioMérieux) has 
been shown to be highly sensitive and specifi c for the detection of KPC in K. pneumoniae 202. 
Th e recently introduced rapid screening test CarbAcineto (modifi ed version of Carba NP test) 
effi  ciently detects OXA-type carbapenemases and off ers a cost eff ective solution for detecting 
carbapenemase producers in Acinetobacter spp 291. 
Th e very early identifi cation of the carbapenemase producers, especially in hospital settings, may 
contribute to limiting their spread. Today it may be reasonable to use some rapid diagnostics 
based on phenotypic techniques and combine it with PCR methods. Rapid screening tests 
can effi  ciently indicate the strains to be further tested and verifi ed by PCR and submitted to 
sequencing. 
4.1.3  C. diﬃ  cile-PCR (Study VI)
Th e C. diffi  cile multiplex PCR for the detection of virulence genes of C. diffi  cile proved to be 
sensitive and specifi c (both 100 %) in identifying and screening for the hypervirulent PCR 
ribotype 027-like strain. Today it is known that the same toxin profi le (A+B+, binary toxin+, 
tcdC 18 bp del) includes several PCR ribotypes 292, 293. In this study (Study VI) 730 samples 
were tested using multiplex C. diffi  cile PCR, and 18 % of the strains had a similar profi le with 
PCR ribotype 027. Most prevalent (80 %) was a profi le similar to PCR ribotype 001. With this 
multiplex PCR it is possible to detect strains with large deletions (39 bp and 54 bp) in the tcdC 
gene as well. Such strains are also toxin hyperproducers and are associated with severe disease 
and mortality 186, 294, 295.
Clostridium diffi  cile infection (CDI) diagnosis is usually based on a combination of clinical 
symptoms and laboratory tests. Th e optimal diagnostic algorithm for CDI is yet to be adequately 
defi ned and may vary with the underlying clinical circumstances. Laboratory tests can fall into 
three groups: 1) methods that detect free toxins A and B from stools (enzyme immunoassay 
(EIA) for toxins, stool cytotoxicity assay), 2) methods that detect the presence of a toxigenic 
strain (nucleic acid amplifi cation tests, NAATs, and toxigenic culture, TC) or 3) methods that 
detect the presence of C. diffi  cile (culture, EIA for glutamate dehydrogenase, GDH). A two-step 
protocol is recommended with the initial detection of GDH (gluD gene) by EIA or PCR followed 
by toxin EIA 194, 296. Today it is known that the sensitivity of EIA is low compared to PCR, and 
NAATs are recommended 297, 298. NAATs are promising due to their high sensitivity and rapidity, 
despite their cost. Nevertheless, there are limits to these new methods, in particular the lack of 
specifi city. Th ese methods can also detect asymptomatic patients who carry a toxigenic strain, 
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but who have diarrhea for some other reason 299. It is shown that the detection of toxin is an 
essential step in the diagnosis of C. diffi  cile infection 300. Aft er the publication of the multiplex 
PCR assay described here, the detection of GDH has been introduced into the process. More 
recently, several commercial real-time PCR solutions have been developed, such as Prodesse 
ProGastro CD, the BD GeneOhm Cdiff , and GeneExpert assays, for detecting toxigenic C. 
diffi  cile 301. Th e multiplex assay in this study is designed to be performed from colonies on CCFA 
plate and is not validated for clinical samples. Th is robust, low-cost, conventional multiplex PCR 
correlated excellently with the PCR ribotypes, especially with PCR ribotype 027-like, and also 
excluded strains with large deletions. More rapid screening using commercial solutions may be 
desirable. A possible further study is to establish a multiplex real-time PCR performed straight 
from a clinical faecal sample. 
In HUSLAB the multiplex PCR has been used to screen every culture-positive C. diffi  cile sample 
since the end of 2007, and it was a current trend in diagnostics of C. diffi  cile at the time 302. 
Interestingly, the proportion of hypervirulent PCR ribotype 027 strains is dramatically decreased 
in the HUSLAB material. In 2008 the proportion of hypervirulent strains was approx. 20 % of all 
toxigenic C. diffi  cile isolates and in 2014 it was less than 1 % of the isolates (Figure 8.) It is known 
that the molecular epidemiology of C. diffi  cile is varied; a certain ribotype can predominate in 
a particular area during certain periods and at the same time be extremely rare elsewhere 293, 303. 
More controlled prescription of antibiotics may also have an eff ect on the disappearance of CDI. 
In addition, rates of CDI, most notably PCR ribotype 027 in the UK and other parts of Europe, 
appear to have declined in the last 4 years and between the years 2007/2008 and 2010/2011, there 
was a 42.9% decrease in the number of PCR ribotype 027 strains isolated from C. diffi  cile 304. 
Th is has occurred simultaneously with an increase in a variety of other PCR ribotypes, especially 
014/020, 015, 078, 005, 023 and 016. Th is phenomenon may refl ect the success of control 
measures to reduce cross-infection in hospitals. Th e annual incidence rate of CDIs decreased 
by 24 % from 2008 (119/100 000) to 2010 (90/100 000) in Finland 305. A total of 5725 cases of 
C. diffi  cile was found in Finland in 2014 and 90 % of them were toxin producers. Th e incidence 
varied between 37–206/100 000 depending on the regions 306. Th e reason for this might be the 
diff erences in the diagnostic methods or diff erences in the prevention and controlling of C. 
diffi  cile. Increased sample submission may also be expected to lead to an amplifi cation of the 
relative contribution of other C diffi  cile ribotypes.
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Figure 8. Toxin producing C. diffi  cile in HUSLAB between 2008 and 2014. (One isolate per patient 
per year, including screening samples)
4.2  DiversiLab results compared with other typing results 
(Study I, II, III, IV)
Th e repetitive PCR based typing method, Diversilab, was evaluated for detecting high-risk 
clones of bacteria causing HAIs, and on the other hand for typing the bacteria by comparing 
this method to other typing methods, so called gold standards. In this study, comparison of the 
typing methods has been made without any epidemiological tools, and subjective results are 
presented in table 13. 
Table 13. Typing results for repetitive PCR, DiverisiLab.
Bacterium Result in this study
MRSA Suitable only for initial screening in an outbreak investigation. 
Overlay analysis and a more discriminative method (PFGE) is needed.
ESBL Enterobacteriaceae Suitable. Harbored the CTX-M-15 clone.
A. baumannii Suitable. Harbored the OXA-23-like and OXA-58 clones.
C. diffi  cile Suitable for monitoring the spread of C. diffi  cile locally.
Harbored the NAP1/027 clone. Multible methods for typing are 
needed.
Generally, this study showed the DiversiLab results to be reproducible. Th e eff ect of DNA 
isolation, the performing technician, and PCR conditions, and the electropherogram of each 
isolate type was studied with a set of isolates (data not shown). If the process was carried out 
393
243 203
112 86 14 10
1636
1222
1052 1209
1164
1075 1049
0
500
1000
1500
2000
2500
2008 2009 2010 2011 2012 2013 2014
N
um
be
ro
f?i
so
la
te
s
Non?hypervirulent?isolate
Hypervirulent?isolate,?e.g.?ribotype?027
Results and Discussion
Year
56
carefully the profi les were not aff ected by the performer of the DNA extraction or PCR with a 
representative set of samples. Even though more reproducible DNA amplifi cation and isolation 
methods would improve the test, it is reassuring that the same conclusion has been reached by 
other investigators as well 252. Some variation in the quality and amounts of the isolated DNA 
used for amplifi cation was observed and also the thermocycler used may have been a source of 
variation. Th e DNA isolation stage must be maximally successful in order for reproducible results 
to be obtained. In addition, with some isolates the freezing-melting cycle of the template DNA 
between separate PCRs seemed to result in somewhat distinct rep-PCR profi les. With Gram-
positive bacteria (especially C. diffi  cile) there were more diffi  culties in the DNA isolation step 
than with the Gram-negatives. Th is may be due to the remarkable diff erences in the structure of 
the bacterial cell walls. Furthermore, C. diffi  cile has a notably unstable genome 307. 
Th e rep-PCR-system provided results that were easy to analyze, were reproducible and were 
rapid to perform, thus making this system a suitable option for clinical use. A set of 13 samples 
could be performed within a single day. In practice, the rep-PCR profi les were easily stored in 
the web-based library and conveniently analyzed by the soft ware of the system. Th e profi les of 
isolates analyzed at separate time points can be archived in the library and compared at any time. 
Th e system also allows joint libraries for separate laboratories when necessary, but in this study 
the library generated by us was more useful than the one provided by the manufacturer.
4.2.1  MRSA (Study III)
Numerous molecular typing methods, such as PFGE 308 spa typing 309 SCCmec typing 310, MLST 311 
and whole genome sequencing 312 have been developed to identify the clonality of MRSA strains 
and monitor their spread. Th e usefulness of DiversiLab and the comparability to other methods 
e.g. PFGE, MLST and spa typing is well known today 238, 313-316. In this study 69 MRSA strains 
belonging to fi ve distinct outbreaks with precise epidemiological data from the district of Vaasa 
hospital were examined. DiversiLab was able to assign the isolates into only three diff erent 
clusters, but when the pattern overlay function was used, two additional sub-clusters were 
identifi ed. In addition, the DiversiLab system was evaluated using 132 MRSA strains from the 
HUSLAB culture collection. 13 diff erent DiversiLab clusters were identifi ed when the combined 
201 isolates were examined. Only in four out of the 13 clusters all the methods (spa typing, PFGE 
and DiversiLab) compared yielded identical results. As a result, the DiversLab system proved to 
be a useful tool for a fi rst-line outbreak analysis, but overlay analysis is needed. Unfortunately 
DiversiLab lacks resolution to diff erentiate genetically and epidemiologically unique MRSA 
strains and DiversiLab has been shown to be less discriminatory than PFGE when comparing 
outbreak strains 313.  On the other hand, the results obtained with spa typing had a weaker 
discriminatory power than the overlay analyses of DiversiLab, causing limited feasibility in an 
outbreak situation. Even though the discriminatory power of PFGE is higher than that of spa 
typing, spa typing is useful to complement the detailed epidemiological investigations 317. Spa 
typing has been claimed to have strong discriminatory power 318 and even though the region X 
of the spa gene was reported to be stable 319, the variability in spa types was seen in this study. 
Several PFGE strain types collected from diff erent part of Finland were typed as spa t008, which 
was the most prevalent spa type in this study.  Th e PVL positive MRSA spa type t008 is identifi ed 
as a variant of USA300 317, which is a predominant community associated MRSA in the USA 73, 320.
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Combined with epidemiological data, PFGE and DiversiLab with overlay analysis were the 
typing methods converging best. Th e same result has been obtained by other researchers as 
well 314, 315. PFGE is oft en considered the gold standard for typing MRSA isolates in epidemiological 
studies. Th is method is known to be highly discriminatory, but technically demanding and time-
consuming 223, 321. Th erefore, the determination of sequence polymorphism in the variable X 
region of the spa gene has become one of the primary typing methods for regional and national 
MRSA surveillance programs. 
Controlling MRSA epidemics is of outstanding importance and therefore rapid detection of 
MRSA clusters and outbreaks is needed. Predominant focus on control eff orts take place in 
health-care facilities. HA-MRSA lineages are usually poorly adapted for persistence in the 
community 71. Lineages of community-associated MRSA, such as USA300, have undergone a 
fundamental shift  and these strains can be carried for long periods by healthy people. Today 
whole genome sequencing holds great promise for rapid and accurate identifi cation of 
bacterial transmission pathways and characterization of outbreaks in hospitals and community 
settings 312, 322. 
4.2.2  ESBL producing Enterobacteriaceae (Study II)
DiversiLab has been evaluated as a useful tool for screening E. coli outbreaks 249, 323. In the 
outbreak characterizated in this study, 39 ESBL producing Enterobacteriaceae (16 E. coli, 6 
K. pneumoniae, 5 K. oxytoca and 12 E. cloacae) isolates from the pediatric surgery ward were 
examined. Th e main β-lactamase enzymes found were CTX-M-15 (23 isolates) and CTX-M-9 
(four isolates). In addition OXY enzymes in K. oxytoca K1 strains were detected. CTX-M-9 
emerged fi rst and was then replaced with the CTX-M-15 enzyme (Table 14). It is speculated by 
Peirano et al. that the successful spread of E. coli producing CTX-M-15 is due to the following 
mechanisms: the spread of an epidemic clone (such as ST131) with selective advantages (such as 
multiple antibiotic resistance and enhanced virulence factors) between diff erent hospitals, long-
term care facilities or wards and the community, and the horizontal transfer of plasmids or genes 
that carry CTX-M-15 alleles 112.
Table 14. Th e time continuum of the ESBL isolates found in the pediatric surgery ward. Due to the 
clonality of E. cloacae isolates they were all considered as CTX-M-15-positive.
Year 2004 2005 2006 2007 2008
Apr May-
Jun
Jul Aug-
Sep
Oct Nov Dec Jan Feb Mar Apr May
E. coli -main 
clone
XX X X XXXXX X X
E. coli X XXX X
K. pneumoniae 
-main clone
X
X
X
K. pneumoniae X X X
K. oxytoca K1 
strains
XXX X
K. oxytoca X
E. cloacae 
-main clone X XXX
X X XXXXX X
red: CTX-M-15, blue: CTX-M-9, black: no CTX-M found
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Clearly one epidemic clone among the E. coli, E. cloacae and K. pnemoniae isolates was identifi ed 
by rep-PCR (DiversiLab, DL, study II) in the outbreak. All isolates of the main clones were shown 
to harbor CTX-M-15 (due to the clonality of E. cloacae isolates they were all considered as CTX-
M-15-positive). In addition, the epidemic E. cloacae strain was isolated from the shower of one 
patient room. Th ese organisms can spread from one patient to another and may also colonize the 
environment in the hospital 324. It seems that E. cloacae ST114 might be the most prevalent clone 
in the dissemination of CTX-M-15, but its dissemination has not been evidenced in one clone 325.
In comparison of the isolates typed with PFGE the main clones were PFGE type A (two subtypes 
being A1 in E. coli and K. pneominiae). Th e main DiversiLab clones embodied eleven of the 
sixteen E. coli isolates and all twelve detected E. cloacae isolates. In addition three of the four K. 
pneumoniae isolates with CTX-M-15 formed one clone.  
With Enterobacteriaceae the discriminatory capabilities of DiversiLab and PFGE were 
comparable. Th e DiversiLab results were supported by PFGE, even though it was more 
discriminative. It is reported that DiversiLab may overestimate the genetic relatedness 249. In this 
study the MLST types were not determined. It is also known that DiversiLab may be slightly 
more discriminative than MLST with K. pneumoniae and E. coli 251, 326. Th e defi ciency of this 
study was that plasmid analyses were not performed.
Th e majority of the ESBL isolates of this study represented two distinct populations of E. coli and 
E. cloacae. Th e main clones found with rep-PCR harbored the CTX-M-15 enzyme. Th e clonal 
dissemination of a distinct strain of either species has occurred in the ward. CTX-M-15 is the 
most universal type of ESBL among E. coli isolates and has been associated with the presence of 
clone ST131 140, 327, 328. Th e worldwide dissemination of E. coli harboring CTX-M enzymes has been 
very effi  cient and has involved health care settings, community, livestock, companion animals, 
wildlife and the environment 329. Also rapid dissemination of CTX-M-genes in commensal E. 
coli isolates in healthy children 330 and within households 331 has been described. Th e DiversiLab 
method could be a rapid option in outbreak investigations and it has the potential to indicate the 
occurrence of a clonal spread 252. 
In conlusion, a clonal outbreak of E. coli and E. cloacae was detected by DiversiLab in one ward, 
and the patients with ESBL were cohorted in the ward at the end of March 2008. Th e ward 
underwent thorough cleaning and no new patients were admitted, until all the cohort patients 
were discharged or placed in an isolation ward. Th e control measures to inhibit the spread of 
ESBL-producing Enterobacteriaceae present a major challenge, because the epidemiology of 
ESBL-producing bacteria has become more complex with increasingly blurred boundaries 
between hospitals and the community 93. In our case the DiversiLab method was found to be 
suitable for the rapid investigation of a local outbreak. In addition, the DiversiLab system has 
been proved to successfully identify the CTX-M-15 producing E. coli clone ST131 248. In the 
future the next generation sequencing has the potential to provide typing results and detect 
resistance genes in a single assay 332.
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4.2.3  A. baumannii (Study I)
For Acinetobacter the DiversiLab system has been proved to be a suitable system for screening 
clonal spread 155, 247, 323, 333. Among 55 A. baumannii isolates two main clonal groups were detected, 
one harboring OXA-23-like genes and the other harboring OXA-58 genes. A time-dependent 
clonal variation was clearly observed. Th e OXA-58 clone predominated and was later substituted 
by OXA-23 clone. Th is replacement has been reported since 2009 in many countries and has 
been explained by the selective advantage associated with the higher carbapenemase activity of 
OXA-23 and/or acquisition of carbapenemase resistance through horizontal gene transfer 160. In 
this study OXA-58 isolates having lower MIC-values to meropenem and imipenem than OXA-23 
isolates were found, as well. Th e insertion of the ISAba1 element located upstream of OXA-51 
gene was not found. Th is junction provides promoter sequences that trigger the overproduction 
of carbapenemase, resulting in a high level of carbapenem resistance 334.
It has been approx. 20 years since the fi rst description of European clonal lineages I and II 335 
and 30 years since the fi rst acquired OXA was found (161). Th e spread of acquired OXAs is well 
documented. In 2010 eight clonal lineages in A. baumannii (WW1-WW8) distributed worldwide 
were typed by Higgins et al. using DiversiLab 155. Th e majority of the carbapenem-resistant A. 
baumannii  from European countries belonged to EUI and EUII and harbored OXA-23, OXA-
24/40  or  OXA-58 genes. Th ey found identical rep-PCR patterns associated with isolates from 
diff erent continents harboring OXA-23 or OXA-58 genes, suggesting clonal spread of a resistant 
organism. Resistance determinants were not associated with a particular cluster; rather each 
cluster contained more than one resistance gene type. Th is suggests that carbapenem resistance 
has developed aft er or during the spread of the clonal lineages 155. Variation within isolates 
harboring the OXA-23 gene identifying seven diff erent clones among OXA-23 isolates has been 
detected by Cielinski et al. 247. In our study only four isolates with the OXA-23 gene did not 
belong to the main clone, but instead six isolates without an acquired OXA gene were clustered 
in the main clone. Higgins et al. have also used DiversiLab in studing the clonality of other A. 
baumannii complex members (A. pittii and A. nosocomialis) and noticed that these do not apper 
to be as widespread and are less clonal in nature than A. baumannii. With A. baumannii they also 
found good correlation between MLST and rep-PCR clusters 333.
Th e current worldwide dissemination of the OXA-23 gene is driven by more than seven MLST 
types (most common STs were ST22/ST2) associated with diff erent genetic structures and 
plasmids. A single clone can have a diff erent genetic structure at the origin of the blaOXA-23 
acquisition. Th e OXA-23 gene associated with composite transposon Tn2006 can be located in 
the chromosome or in a plasmid 285. Complex and dynamic spreading of OXA-23 will be diffi  cult 
to control because this spread is not associated with a single entity. 
Controlling an endemic  A. baumannii  infection in hospitals is very diffi  cult. Acinetobacter is 
widely present in diff erent ecological niches. Th e ubiquitous presence of A. baumannii in nature 
and consequent isolation from water, animal, and soil samples may have led to its signifi cance 
being underestimated 336.. Th e existing approaches consist of environmental disinfection involving 
the use of potent products together with an intensive educational program that promotes hand 
hygiene and contact isolation into cohorts and even selective decontamination 337. Th e clonal 
spread of OXA-23-producing A. baumannii has led to an increased need for appropriate 
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infection control measures that can prevent further spread of these multidrug-resistant 
organisms 338, 339. Th e suggestion is that the DiversiLab method might be a useful tool for rapid 
epidemiological screening of A. baumannii and help to prevent the clonal spread. In the future 
large-scale sequencing, more closely NGS, and genotyping of A. baumannii strains provides a 
comprehensive genetic data that is useful in molecular epidemiology 340.
4.2.4  C. diﬃ  cile (Study IV)
C. diffi  cile rep-PCR fi ngerprints were performed for 181 clinical isolates by DiversiLab. In 
addition, isolates with large tcdC-deletions (n=24) were studied. Th e results of the clinical 
isolates were compared to PCR ribotyping, PFGE, virulence genes and tcdC gene sequencing 
(unpublished data) (Table 15). Th e most prevalent PCR ribotypes were 027 (64/181, 31%) and 
001 (54/181, 26%). Th e rest of the isolates (63/181) represented a total of 29 diff erent PCR 
ribotypes. PCR ribotypes 002, 014 and 020 were the most prevalent among them (25/63, 40 %) 
and over half of the PCR ribotypes 002, 014 and 020 isolates were grouped to a single clone with 
DiversiLab. It is known that ribotypes 014 and 020 are closely related, and in PCR ribotyping 
diff er only by one band 341. PCR ribotypes 014 and 002 were common among the clinical isolates 
in Europe at the time of the sudy by Barbut 342. Th ese types of isolates have not been reported to 
cause a severe disease. Th ey are common in humans and are also present in water and various 
animals 343.
At the time of the study by Kotila et al 344, the PCR ribotype 027 was found to be the most 
prevalent PCR ribotype in Finland, followed by ribotypes 001, 002 and 014. Type 027 was usually 
the dominant PCR ribotype among the isolates from severe cases and outbreaks 344.
Using rep-PCR analysis, a total of 28 diff erent profi le groups were identifi ed, but only six major 
rep-PCR groups could be detected (DL1-DL6). In 75% (135/181) of the isolates the classifi cation 
obtained by rep-PCR and PCR ribotyping (including toxin hyperproducers PCR ribotypes 027, 
001, 023) was comparable (Table 15). Th e correlation of rep-PCR, PCR ribotyping and PFGE 
was excellent with the two major groups (DL1 and DL2) of isolates, PCR ribotypes 027 and 001. 
Within other isolates, the grouping obtained by these three methods was more heterogeneous 
and there were inconsistencies in results between PCR ribotyping and rep-PCR. However, in 
some cases PFGE supported the rep-PCR clustering.
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One clone was clearly detected within PCR ribotype 027 by rep-PCR. Contrary to the results 
of this study, subgroups among the PCR ribotype 027 have been found (Healy et al. 19th 
European Congress of Clinical Microbiology and Infectious Diseases, abstract P1731) 264, 292, 345. 
In these studies four diff erent subgroups have been identifi ed among PCR ribotype 027 when 
comparing rep-PCR to PCR ribotyping and PFGE. Heterogeneity within PCR ribotype 027 
has been reported by MLVA as well 345. MLVA has been used to discriminate between isolates 
with identical PCR ribotypes belonging to types 001, 017 and 027 346. Th is heterogeneity of PCR 
ribotype 027 may be due to actual diff erences between the strains circulating in the diff erent 
geographic areas 303. PCR ribotype 027 had recently emerged in Finland at the time, the fi rst PCR 
ribotype 027 having been identifi ed in 2007 193. Th e isolates in Finland were most likely clonal 
because the variation over time had not yet evolved. Today it is known that PCR ribotype 027 
is genetically variable and it appears that the recently identifi ed PCR ribotypes 019, 176, 244 
and 198 293, and in addition PCR ribotypes 016, v046, 080 347, have evolved from the 027 lineage. 
Th ese are closely related outliers to hypervirulent 027 clones that can be misclassifi ed as 027. 
It is important to develop more accurate methods to distinguish between these highly virulent 
strains. Understanding the evolution of clones such as the PCR ribotype 027 will be important in 
predicting the early emergence (or disappearance) of highly virulent C. diffi  cile strains 292. 
When all of the 181 clinical isolates were compared to each other, the most prevalent PCR 
ribotypes (027 and 001) clustered in their own rep-PCR groups and both had a typical well 
identifi able electropherogram. Interestingly, when comparing only PCR ribotypes 001 to each 
other, four rep-PCR subgroups and one outlier could be detected. It proved that sometimes 
DiversiLab is more discriminatory than PCR ribotyping. Th is phenomenon within PCR ribotype 
001 has also been reported by other reseachers 348, 349.
In this study the two other potentially hypervirulent toxin hyperproducers (PCR ribotypes 
023 and 078) were also found to cluster in their own rep-PCR groups when all the consecutive 
181 clinical isolates were compared to each other. Within the large deletions more specifi c 
investigation was performed.  Among tcdC-A (39 bp deletion, classifi cation as in Curry et al. 
179 three diff erent PCR ribotypes, 045, 078 and 126 were detected and results with DiversiLab 
were highly heterogenic. Genetic diversity among PCR ribotype 078 has been shown, but PCR 
ribotypes 078, 126, 033 and 045 have proved to be highly related in MLST 350. Th e variation 
is suggested to be due to multiple sources of this ribotype 187, 264. With these isolates, PFGE 
supported neither PCR ribotyping nor rep-PCR but led to a third delineation of isolates. Among 
tcdC-A variant (54 bp deletion, classifi cation in this study) all but one of the isolates were of PCR 
ribotype 023 and with DiversiLab one main clone harboring 11 out of 14 isolates was detected. In 
PFGE these tcdC-A variants represented one PFGE type and its three subtypes.
TcdC gene sc-classifi cation for all the 181 clinical isolates was determinated according to Curry 
et al. 179. Most prevalent tcdC genotypes were tcdC-sc1 (65/181) and tcdC-sc3 (59/181) (Table 
11). TcdC-sc1 genotypes contain 18 bp deletion at nucleotides 330 to 347 and were all but 
one typed as PCR ribotype 027. Th is one exception was an unknown 44 which was typed as 
NAP1 with PFGE and had the same DiversiLab type, DL1 as PCR ribotype 027. In addition, 
one genotype of tcdC-sc2, which is identical to genotype tcdC-sc1 except for the insertion of a 
single nucleotide at position 212 was found. Two genotypes of the tcdC-A (39 bp deletion) and 
fi ve genotypes of the tcdC-A variant (54 bp deletion) were found. In addition to wildtypes, one 
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genotype of tcdC-sc5, one genotype of tcdC-sc7 and six genotypes of tcdC-sc15 t were found. It is 
known today that tcdC deletions may not be the sole factor responsible for the increased toxin 
production observed. It could be predicted that toxin production could be amplifi ed as the result 
of a missense or nonsense tcdC mutation. Recent studies, however, have failed to confi rm such 
eff ects in the settings of deletions of larger gene sequences 182. Th e presence of a binary toxin gene 
and tcdC SNPs at position 184 and 117 has proved to strongly predict the recurrence of CDI 351. 
Several typing methods have been used for C. diffi  cile. It has been shown that MLVA, REA, 
slpAST (surface layer protein A gene sequence typing) and PFGE are more discriminative than 
PCR ribotyping, MLST and AFLP 197. Th e rapid clonal spread of the hypervirulent PCR ribotype 
027 strain has brought along the need for rapid detection. At the time of this study PCR ribotype 
027 strains were clearly separated to one cluster using rep-PCR. Th us, the rep-PCR method may 
be adequate for the investigation of a local outbreak by rapid screening of the hypervirulent PCR 
ribotype 027 strains. It is a useful tool for local clinical laboratories in monitoring the spread of C. 
diffi  cile for instance in hospital wards, but all the analyses should be performed in one laboratory. 
C. diffi  cile has a highly mobile, mosaic genome, which may have an eff ect on the results and DNA 
degradation, typical for C. diffi  cile, interfering with the analysis 307. None of these three methods 
(DiversiLab, PCR ribotyping and PFGE) were unanimously more discriminative than the other 
two, and the results revealed discrepancies. 
PCR ribotyping as a current European reference typing technique relies more on the comparative 
ease of the technique and repeatability than on the discriminatory ability. PCR ribotyping can be 
performed in two days for a set of 17 samples 352. More recent studies have begun to recognize 
the comparative lack of discrimination of this technique and are favoring more discriminatory 
techniques, such as PFGE and MLVA, for diff erentiating isolates having identical PCR ribotype 
profi les 197, 226. Even if PFGE is discriminatory, it has a very low throughput due to the length of 
the procedure (taking four to eight days to complete) in comparison with PCR-based genotyping 
methods 232. PFGE is claimed to be labor-intensive and it delivers optimal results when performed 
by a technician with extensive experience using this method. In conclusion, it is advisable to use 
multiple methods for typing C. diffi  cile. Th e whole-genome sequencing (WGS) has signifi cantly 
furthered the knowledge of the genetic diversity, evolution, epidemiology, and pathogenicity of 
this once enigmatic pathogen. Th e numbers of sequenced and analyzed partial genomes of C. 
diffi  cile have increased rapidly 353.
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5.  CONCLUDING REMARKS AND FUTURE 
PROSPECTS
5.1  Summary
Rapid detection in clinical laboratories is essential for the prompt recognition of antimicrobial-
resistant organisms. Infection-control practitioners and clinicians need the clinical laboratory 
to rapidly identify and characterize diff erent types of resistant bacteria to effi  ciently control the 
spread of these bacteria and to help select more appropriate antibiotics. 
Th ere are several problems for a clinical laboratory wishing to adopt a rapid, reliable and 
sensitive PCR-method to solve, such as opening hours of the laboratory including logistics of 
the samples, costs, and equipments needed. Th e aim of the current study was to develop new 
multiplex PCR methods for the precise characterization of hospital-acquired bacteria and to 
compare automated rep-PCR to other typing methods in a compact set of consecutive samples 
or retrospectively collected strains without the associated epidemiological data. Epidemics cause 
additional costs in health care. Microbiological screening plays a major role in these costs. When 
molecular biological techniques are applied, the analytical costs decrease. 
A rapid negative or positive screening result of hospital-acquired bacteria can be valuable when 
the colonization status of a patient is needed. For example, on admission to an intensive care unit 
possible carriers should be detected as soon as possible. Also rapid reporting that the patient is 
not a carrier is of great importance. Th e responsibility of the laboratory is to avoid unnecessary 
and costly screening methods and to aim at achieving reliable and sensitive methods of detection 
of notorious hospital-acquired bacteria. 
Many of the molecular techniques currently used for typing still rely on electrophoretic separation 
of DNA fragments of diff erent molecular lengths. Th e electrophoretic result is represented by a 
pattern of bands on a gel. Since these patterns may be extremely complex, the ease with which the 
patterns are interpreted and related is an important factor in evaluating the utility of a particular 
typing method. As ease of use is important, the technical diffi  culty, cost, and time to obtain a 
result must be evaluated in assessing the utility of a particular typing method.
In this study the samples were collected mainly from the district of Helsinki and Uusimaa, 
during a limited time frame. At the time of the study the fi rst fatal hypervirulent C. diffi  cile 
strain (PCR ribotype 027) and the fi rst CPE strains emerged in Finland. Regarding HAIs in 
general, however, the situation in Finland is quite good, except for C. diffi  cile where the success 
in controlling the disease has varied between regions. Th ree diff erent usable multiplex PCRs 
for rapid identifi cation of bacteria causing outbreaks were established and each of them is still 
in daily use in routine diagnostics. We succeeded in performing a reliable outbreak analysis at 
hospital level with methods used in this study. Th e semi-automated repetitive PCR based typing 
method was found to be benefi cial in the fi rst-line outbreak analysis at local level. Th e utility of 
DiversiLab was more obvious with ESBLs and A. baumannii than with MRSA and C. diffi  cile. 
Th e usefulness of the rep-PCR with isolates collected from a larger geographical area, or during 
a longer period of time remains yet to be studied. Diff erences in specifi c bacterial properties and 
the levels of discrimination required by a particular bacterial species must be taken into account 
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when selecting the most applicable typing technique. In conclusion, the gold standard methods 
are still needed in global epidemiology.
Th e automated rep-PCR system proved to be an easy-to-use, reproducible, fast and discriminative 
tool. In outbreak situations it is of vital importance that the screening method does not fail to 
identify related epidemic isolates. Th e automated rep-PCR system was found to be reliable in this 
respect. We thus suggest that it may be useful in the rapid analysis of outbreaks caused by ESBL 
producing Enterobacteriaceae and A. baumannii.
5.2  Future prospects
Fast and accurate identifi cation and typing of pathogens is essential for eff ective surveillance 
and detection of outbreak. Th e current routine procedure is based on a variety of techniques, 
making it laborious, time-consuming and expensive. In this study we concluded that the costs of 
the DiversiLab method are quite high, thus limiting its use. Th e future will show whether high 
throughput sequencing methods (next generation sequencing or massive parallel sequencing) 
will replace the classic DNA-based typing methods. Whole genome sequencing might be the 
solution which has huge potential in both diagnostic and routine surveillance. 
NGS has many advantages over other existing molecular approaches, including throughput, 
higher resolution, better effi  cacy, cost effi  ciency, fl exibility, scalability and less hands-on-
time. Th us it may potentially replace a multitude of assays currently used simultaneously in a 
diagnostic microbiology laboratory. It has been demonstrated that SNPs mined from whole 
genome sequence (WGS) data as well as gene-by-gene (MLST) comparisons provided greater 
resolution for the detection of an outbreak and for the tracking down of microbial strains for a 
wide range of bacterial pathogens than current gold standard methods. Additionally, the growth 
of public databases harboring reference genomes continues to enhance the utility of NGS in 
public health and in clinical practice 354. Th ere are still some methods not easily replaceable, such 
as PFGE, methods based on repetitive sequence, serotyping within certain species, and expressed 
microbial drug resistance. 
Matrix-assisted laser desorption ionization–time of fl ight mass spectrometry (MALDI-TOF-MS) 
has become a widely used technique in routine clinical laboratories for bacterial identifi cation. It 
has replaced previous techniques, but a lot of work remains to be done before it can be used for 
the detection of, for example, antibiotic resistance in the clinic.
A challenge for future research is to sequence the strain settings studied comprehensively in 
this thesis using NGS techniques. We aim to start with ESBL producing Enterobacteriaceae and 
compare the sequence results with typing results received in this study. Th is study, however, 
suggests the need for new gold standard approaches for the typing of molecular epidemiological 
strains.
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